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CLINICAL ADVANCES 
IN MEDICAL AND SURGICAL NEUROLOGY 
PART II 
\ 
When cardiac 
complaints occur 
in the absence 
of organic findings, 
underlying 
anxiety may be 
one factor 
The influence of anxiety on heart function 
Excessive anxiety is one of a combina, 
tion of factors that may trigger a series of 
maladaptive functional reactions which can 
generate further anxiety. Often involved in 
this vicious circle are some cardiac arrhyth, 
mias, paroxysmal supraventricular tachycar, 
dia and premature systoles. When these 
symptoms resemble those associated with 
actual organic disease, the overanxious 
patient needs reassurance that they have no 
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organic basis and that reduction of exces, 
sive anxiety and emotional overreaction 
would be medically beneficial. 
The benefits of antianxiety therapy 
Antianxiety medication, when used to 
complement counseling and reassurance, should 
be both effective and comparatively free from 
undesirable side effects. More than 13 years of 
extensive clinical experience has demonstrated 
that Librium (chlordiazepoxide HCl) fulfills 
these requirements with a high degree of con, 
sistency. Because of its wide margin of safety, 
Librium may generally be administered for ex, 
tended periods, at the physician's discretion1 
without diminution of effect or need for increase 
in dosage. If cardiovascular drugs are necessary, 
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is a clinically significant factor. Librium should 
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INTRODUCTION 
This issue represents the second part of the 27th 
Annual Stoneburner Lecture Series delivered at the 
Medical College of Virginia in February 1974. The 
first part emphasized basic and clinical aspects of 
cerebral vascular disease and basic mechanisms in 
brain injury and was published in the preceding issue 
of the MCV/ Q. 
Here, we are dealing with clinical applications of 
recent advances in our understanding of brain mech-
anisms and brain disease processes. The Stoneburner 
Lecturer was Dr. Thomas W. Langfitt, the Charles H. 
Frazier Professor and Chairman of the Division of 
Neurosurgery at the University of Pennsylvania. 
DONALD P. BECKER, M.D. 
Professor and Chairman 
Division of Neurosurgery 
Medical College of Virginia 
Virginia Commonwealth University 
Clinical Advances 1n the Management of 
Patients with Severe Head Injury* 
THOMAS W. LANGFITT, M.D. 
Charles H. Frazier Professor and Chairman, Division of Neurosurgery, 
University of Pennsylvania, Philadelphia 
Some of the physiological properties of the 
cerebral circulation, intracranial pressure and brain 
metabolism, as well as some of the patho-
physiological alterations that we see with various 
types of brain injuries have been discussed in this se-
ries. We are going to see how we can apply some of 
this information clinically. I will begin with a patient. 
A patient, comatose following a severe head iri-
jury, is brought into the emergency room. Our 
method of managing these patients has evolved over 
a number of years. Although I shall present the 
procedure to you sequentially, in fact, much is done 
virtually simultaneously. As always, the first thing 
that one must attend to is the airway. The majority of 
comatose head-injured patients, upon admission to 
the emergency ward, have a hyperventilation syn-
drome. It is of primary necessity, in this situation, to 
obtain an arterial blood sample for measurement of 
Pa0 , Paco, and pH. Frequently, the patient is 
hypocapni~, with a Paco, of perhaps 30, and is hypox-
ic as well. In a large series from several clinical units, 
the average Pa0 , of several hundred patients at the 
time of admission was about 65-70 mm Hg-
somewhat hypoxic but generally not severely so. 
How can the patient be hyperventilating, be 
hypocapnic, and hypoxic at the same time? Nearly all 
of these patients have some degree of pulmonary 
aiteriovenous shunting but are able to eliminate the 
C02 with their relatively inadequate respirations, 
because C02 diffuses across the alveolar membrane at 
• This is an edited transcription of a lecture presented by Dr. 
Langfitt at the 27th Annual Stoneburner Lecture Series, February 
8, 1974, at the Medical College of Virginia, Richmond. 
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twenty times the rate of oxygen. At the same time, 
they are not able to get enough 0 2 into the blood. 
Hypoxia and hypocapnia are a very common 
pulmonary syndrome in these patients. 
if the patient looks as though he is severely brain 
injured and is not going to recover soon, we go straight 
to intubation after drawing the arterial blood gas. 
The patient's airway is cleaned and he is then ven-
tilated with an Ambu® bag. By now, someone is taking 
the blood pressure and the heart rate. If the patient 
has a mass lesion, then, in a majority of cases, he has 
a so-called Cushing response consisting of arterial 
hypertension. He may or may not have bradycardia; 
in fact, in our experience, in the acute brain injured 
patient; tachycardia is more common than bradycar-
dia, except in those patients with acute extradural 
hematomas. A decision must be made now as to how 
to manage the patient over the next hour. We give 
dexamethasone (10 mg IV), although I am not at all 
convinced that the patients are benefitted by it. If the 
patient is in extremis, we give 1.5 mg/kg of hyper-
tonic mannitol by IV push, in the hope of buying time 
for angiography. We like to have angiography for all 
of these patients as soon as possible. It must be 
remembered, however, that if done within an hour or 
two of the injury, one may miss the hematoma that is 
in the process of developing. If the neurosurgeon in 
charge feels that there is not time for an angiogram, 
the surgeon may perform exploratory burr holes. We 
avoid this operation if possible, since we feel that 
angiography gives so much information. (The 
technique mentioned in Dr. Vries' presentation of in-
serting a ventricular cannula, injecting some air, and 
then treating the patient immediately, depending 
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upon what that air study shows is impressive; if the 
patient has a shift, take him directly to the operating 
room.) If the patient does not have a mass lesion, a 
Scott cannula is placed through a twist drill hole into 
the anterior horn of the right lateral ventricle, in 
order to measure intracranial pressure continuously. 
If the patient goes to the operating room and has a 
mass lesion removed, the Scott cannula is put into the 
anterior horn of the lateral ventricle at the time of 
surgery. 
The patient is then returned to the neurosurgical 
intensive care unit, where we go through a number of 
procedures which will constitute the bulk of my dis-
cussion. Figure l is simply an artist's sketch of the 
Scott cannula in the anterior horn of the right lateral 
ventricle at the level of the coronal suture. Again, 
Figure 2 is an artist's sketch of the patient in the in-
tensive care unit with the head dressing and the Scott 
cannula. The transducer is wrapped in a sterile towel 
because there is a risk of infection from an inside-
outside connection of CSF, and this requires 
meticulous technique. In 350 cases, we have had an 
infection rate of about 2%, which compares favorably 
with Lundberg's 1.6% infection rate in something 
Fig. I 
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Fig. 2 
over 1,000 patients with continuous recording of in-
tracranial pressure. We would like to get rid of the in-
traventricular cannula, because we consider 2% to be 
still too high, but we do not feel, at this time, that 
there is an adequate solid state transducer for 
measuring intracranial pressure. 
Figure 2 also shows a two channel strip chart 
recorder. One channel records the intracranial 
pressure and the other, systemic arterial pressure 
from a catheter in either the radial or the brachia) 
artery. 
At this point, we prepare to do regional cerebral 
blood flow and metabolism studies. We use the 133Xe 
clearance technique, in order to measure regional 
cerebral blood flow (RCBF). Xenon is injected 
through a catheter placed under fluoroscopic control 
into the internal carotid artery and the xenon is then 
injected as a bolus. The xenon enters the brain, 
diffuses into the brain tissue, and is then cleared from 
the tissue over a period of about 15 minutes. The rate 
of clearance from each region under study determines 
the blood flow; therefore, the faster the rate of 
clearance, the faster the flow. There are a number of 
ways of examining and analyzing these clearance 
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curves. We feel, for our purposes, that eight probes 
for measuring RCBF over each hemisphere are per-
fectly adequate. There are, however, extremely 
sophisticated systems in which it is possible to 
measure the RCBF from as many as 250 regions. 
In addition, a second catheter is placed per-
cutaneously into the jugular vein and passed well up 
into the intracranial space, into the sigmoid sinus, in 
order to obtain a cerebral venous blood sample. 
Periodically during the course of the clinical in-
vestigation, simultaneous samples of blood are taken 
from the artery (from the internal carotid artery, in 
this case) and from the jugular bulb, from which it is 
possible to calculate the cerebral metabolic rate of 
oxygen (CMR0 ). Studies on the cerebral metabolic 
rate of glucose, 2lactate, and pyruvate have been done 
as well. In fact, if one's techniques are sophisticated 
enough, accurate enough, in theory at least, it is pos-
sible to measure anything that the brain utilizes l:Jy 
measuring the content in both the arterial blood and 
the cerebral venous blood. Here we shall discuss only 
CMR0 , , oxygen utilization . First, we determine the 
0 2 content in both the arterial and venous samples; 
CMR0 is equal to the arteriovenous difference of 
oxygen' content times the mean cerebral blood flow 
divided by 100. 
Table I shows a selection of the normal values, 
such as CBF, approximately 50 ml/100 gm/ min, 
systemic arterial pressure, about 85. We defined, as 
have others, normal intracranial pressure as less than 
200 mm CSF or less than 15 mm Hg. The cerebral 
perfusion pressure, assuming an ICP of 10, is 75 mm 
Hg, the normal arterial-venous oxygen difference 
(A VD0 ) is 7-a figure to remember. The CMR0 is 
3.5 ml/ JOO gm/ min and the normal values for arte;ial 
blood gases and pH are familiar to you. 
For the sake of example, a single patient will 
now be described in detail. 
A 50-year-old man had been found on the street 
and was brought into the emergency ward comatose; 
he had bruises about the head, indicating that he had 
been bludgeoned, and there were clinical signs point-
ing to a left hemispheric mass with evidence of 
transtentorial herniation . He was given dexa-
methasone and mannitol and was intubated and ven-
tilated with the Ambu® bag. The resident who was 
caring for him felt that he was in extremis, that there 
was not enough time to do an angiogram, despite the 
administration of mannitol; therefore, the patient 
was taken to the operating room for burr holes. 
There was no evidence of an extracerebral 
TABLE I 
Normal values of variables tested 
Variable 
cerebral blood flow (CBF) 
systemic arterial pressure (SAP) 
intracranial pressure (ICP) 
cerebral perfusion pressure (CPP) 
cerebral vascular resistance (CVR) 
arteriovenous blood oxygen content 
(AVDO,) 
cerebral metabolic rate (CMRC,) 
arterial carbon dioxide partial 
pressure (PaCO,) 
arterial oxygen partial pressure 
(PaO,) 
arterial blood acidity (pH) 
Normal Value 
50 ml/100 gm/min 
85 mm Hg 
15mmHg(200 
mmCSF) 
75 mm Hg 
1.70 
7.0 vol % 
3,5ml/100 gm/min 
40mm Hg 
100 mm Hg 
7.35 
(Reproduced by permission of the American Association of 
Neurological Surgeons, and the authors, from D. A. Bruce, et al, 
" Physiological Changes in Brain During Coma," J Neurosurg 
38: 133 , 1973.) 
hematoma; the resident needled the brain one time 
and got no blood, and the Scott cannula was put in 
along with a solid state transducer to measure in-
tracranial pressure. The patient was then taken to the 
angiography suite, where we also do the RCBF and 
metabolism studies. On angiogram, the patient had a 
huge, temporal and deep mass in the hemisphere. The 
Scott cannula was, in this case, placed through a burr 
hole in the lateral ventricle. While the angiogram was 
being developed, we carried out our first RCBF and 
metabolism study. 
Figure 3 demonstrates one of the ways in which 
we display the data. You will note that this patient, 
during the control period, had a mean CBF of 10 
ml/100 gm/ min, one-fifth normal and far below that 
ordinarily required to maintain brain function. The 
patient's mean systemic arterial pressure was 135 mm 
Hg, and the mean intracranial pressure extremely 
high at 107 mm Hg, giving the patient then a cerebral 
perfusion pressure (CPP) of 28. Note that at this 
time, the Pa0 is quite adequate at I 04 and the Paco is 
slightly low. The value for CMR0 -0.71-is one-fifth 
normal. One can state as a gener~l rule, with the oc-
casional rare exception, that any patient with CM Ro, 
less than 1.0 probably will not survive. 
The angiogram showed the huge mass which had 
been missed in the operating room with the single 
pass of the needle. The needle was then inserted into 
the region of the mass and we obtained 70 cc of 
blood. A second postevacuation study was per-
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Fig. 3 
formed, disclosing the reduced mass with the es-
timated increase in CBF from 10 to 18 ml/ I 00 
gm/ min. In the region of the mass, where blood flow 
was virtually obliterated, we had a fourfold increase 
from 6 to 24 ml/100 gm/ min. The intracranial 
pressure dropped from 107 to 47 mm Hg following 
evacuation of the mass. If we were measuring only 
the ICP, we might feel we had really accomplished 
something. The systemic arterial pressure, however, 
was being held up by a Cushing response, secondary 
to the intracranial hypertension . Although we 
markedly reduced the intracranial pressure, the blood 
pressure fell equally, and the perfusion pressure went 
only from 28 to 29; despite that, we did increase CBF 
by 8 ml/100 gm/ min. 
Now, however, another problem arose. The 
patient, comatose but showing slight evidence of 
arousal, went from flaccidity to some decerebrate 
posturing; he also began to hyperventilate, driving his 
Paco from 36 down to 23, but, at the same time, he 
developed acute pulmonary edema. Even though he 
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because of the edema, we now saw his Pa0 dropping 
also, from 104 to 75. ' 
Despite the improvement in the CBF and some 
evidence of clinical improvement, the patient's 
CMRo actually fell from 0.71 to 0.39, which is barely 
one-te~th of normal. We tried to raise his blood 
pressure, hoping to improve his perfusion pressure 
and further improve his CBF, then at 18. Figure 4 
shows the response following angiotensin. We 
brought his SAP up to 129 from 76, but the CBF in-
creased only from 18 to 23, because, with the arterial 
hypertension and the edema fluid, the intracranial 
pressure has gone from 47 to 74 mm Hg. In order to 
comprehend the pathophysiology of these patients, 
one must measure nearly all of these variables. 
Despite his marked hypocapnia and hyperventila-
tion, his Pa0 is still only 67 because of his pulmonary 
edema. We decided to give mannitol, and the patient, 
in terms of CBF, responded dramatically; CBF went 
from 23 to 38, perfectly adequate for a normally 
metabolizing brain, and ICP dropped from 74 to 48. 
was hyperventilating and producing hypocapnia, Fig. 4 
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Marked improvement in CBF occurred, despite the 
fact that the patient's perfusion pressure dropped 
from 55 to 46. A change in fl.ow, of course, will occur 
with a change in perfusion pressure or a change in 
resistance or with a change in both, and, in this case, 
it is quite clear that the mannitol has reduced the 
edema, thereby opening up the microcirculation and 
permitting a marked improvement in CBF, despite 
there being no significant change in the patient's 
CPP. The Pa0 and Paco were the same; the CMR0 
was fluctuating somewh~t. ' 
We continued to battle his intracranial pressure, 
which, however, continued to rise, and finally, as is 
the rule in these cases, the intracranial pressure 
equaled the blood pressure. At this point, the phenome-
non of nonfilling of the cerebral circulation upon 
angiography or injection of 133X became evident. In 
this situation, if one injects radio-opaque media into 
the carotid artery, it will rise up into the internal 
carotid (sometimes to the level of the siphon) and 
then stop. A film taken 30 seconds or a minute later 
will show the opaque dye still sitting in the carotid 
artery, none having entered the intracranial space, 
due to the fact that ICP equals SAP and, therefore, 
CPP is zero. When this occurred in our patient, we 
decided he obviously had all of the clinical criteria of 
brain death. We decided, however, to manipulate the 
blood pressure with a vasopressor agent, Levophed®, 
to see whether we could possibly reestablish a perfu-
sion pressure. These primary changes in systemic 
arterial pressure, produced by altering the rate of drip 
of a vasopressor agent, produced precisely equal 
changes in the ICP. There was no way to reestablish 
perfusion pressure by manipulating the arterial 
pressure. In this patient who had a severe and, as it 
turned out, irreversible brain injury, we were, by 
various types of manipulations, able to raise his CBF 
to something approaching a normal range, but too 
late, and the patient died shortly after this study. 
Now, just a few comments on intracranial 
pressure. Until the publication of Lundberg's land-
mark monograph from the University of Lund in 
Sweden in 1960, we generally thought oflCP as being 
a steady phenomenon; intracranial pressure had been 
measured only through the lumbar subarachnoid 
space in the vast majority of patients. In 1963, we 
demonstrated in experimental animals (using a slowly 
expanding extradural balloon in the monkey), that 
when the intracranial pressure rises by virtue of ex-
pansion of a mass, a dissociation occurs invariably, 
between the supratentorial pressure and the pressure 
of the lumbar subarachnoid space. Finally, with the 
slow expansion of the balloon, when the intracranial 
pressure reached the level of the blood pressure in the 
monkey, lumbar subarachnoid pressure was normal. 
We demonstrated that this also occurs in man. The 
higher the intracranial pressure, the greater the brain 
swelling, the less likely it is that the lumbar sub-
arachnoid pressure will reflect that increased in-
tracranial pressure. Many times in man, lumbar sub-
arachnoid pressure is normal when the intracranial 
pressure is from 50-100 mm Hg. It follows, therefore, 
that one cannot use lumbar subarachnoid pressure to 
determine the actual pressure within the intracranial 
space. All pressure measurements today are done 
directly from the intracranial space by one method or 
another. 
Lundberg then demonstrated that in many 
patients, intracranial pressure is not a steady 
phenomenon; in fact, there are tremendous fluc-
tuations in pressure. He described what he called "A 
waves or plateau waves, B waves, and C waves." For 
the most part, these waves appear to be rather in-
nocuous, there being, usually, no indication of 
neurological deterioration. With the extremely 
dangerous plateau wave, the intracranial pressure is 
reasonably steady, at first, but then fluctuates, and 
finally, inexorably rises-a terminal pressure wave. 
Figure 5 summarizes work that we did some 10 
or 11 years ago. It is a very simple figure but quite im-
portant. This is the volume pressure graph within the 
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intracranial space, actually taken from a series of 
monkeys. We put in an extradural balloon, and then 
slowly inflate it at a rate of l ml/min, while we 
measure the intracranial pressure. Up to a volume of 
about 5 ml in the balloon, there is no significant 
change in intracranial pressure. Why is this? Because 
the intracranial space contains displaceable fluid, 
mainly in the form of CSF but also, to some extent, in 
the form of intravascular blood. Since we are dealing 
with a cavity that is nondistensible, which is filled to 
capacity with a noncompressible fluid and solid 
material, it follows that if indeed we had a completely 
closed system, that is, if we had a sphere made of 
bone filled to capacity with water, and we attempted 
to inject additional water into that cavity, we could 
probably inject no more than 0.1 ml, in the case of the 
monkey; we would get a tremendous rise in in-
tracranial pressure, simply because we cannot stretch 
the shell. We cannot compress the fluid. That is not 
the case in life. We can actually put 5 ml of fluid into 
this monkey's skull (total capacity of 100 ml), 
because of spatial compensation. It means that up to 
a value of about 5 ml, for every l ml that we are put-
ting into the balloon, we are expressing l ml of CSF 
or blood. Then we pass from this period of spatial 
compensation, the horizontal portion of the volume 
pressure graph, onto the vertical portion. Note here 
that between a balloon volume of 7 and 8 ml, the in-
tracranial pressure rises 75 mm Hg. Thus, in the case 
of those patients with pressure waves, those who have 
any kind of mass lesion or brain edema, the bulk of 
them are somewhere on the vertical part of the graph. 
The pressure waves are due to spontaneous 
alterations in cerebral blood volume. The pressure 
waves are reflecting alternating vasodilatation and 
vasoconstriction of the cerebral vascular bed. We do 
not know the reason for this. The vasodilatation 
produces a slight increase in cerebral blood volume. 
That slight increase, however, when the patient is on 
the vertical portion of the volume pressure graph, will 
produce a tremendous change in pressure. The 
patient who presents with a longstanding space-
occupying mass, chronic subdural hematoma or 
meningioma, who has now reached the limits of his 
period of spatial compensation, therefore, may have 
few signs or symptoms, but he is sitting on a time 
bomb as it were. When he goes to sleep, for example, 
he becomes a little hypoxic and hypercapnic. We 
recorded many of these patients in sleep, and indeed, 
their intracranial pressure may rise astonishingly dur-
ing sleep, simply because of a little bit of vasodilata-
tion from the hypercapnia. It follows as well, that if 
one is treating a patient who is on the vertical portion 
of the curve, it is necessary to remove only a small 
portion of any one of the volumes within the in-
tracranial space in order to drop the pressure. We 
have many patients who have had pressure of 80-90 
mm Hg. The removal of no more than 2 ml from the 
ventricle will drop the pressure down to 20-30 mm 
Hg, because they are falling on an extremely sharp 
vertical portion of the curve. 
What constitutes a critical level of intracranial 
pressure for brain function? I have no idea, because it 
varies so much from patient to patient. The more the 
brain itself is damaged, that is, the more the edema, 
the more contusion, then the less tolerant that patient 
is of intracranial hypertension. We have many 
patients, for example, who would not tolerate an ICP 
above 25-30 mm Hg; they would obtund, develop a 
hemiparesis. When we then lowered the pr~ssure to 
10-15 mm Hg, they would improve. Patient~who do 
not have brain damage but, nevertheless, have in-
tracranial hypertension, will often tolerate extremely 
high levels of intracranial pressure. We have seen a 
young woman with severe hydrocephalus from a 
cerebellar hemangioblastoma. She was neurologically 
normal, except for minimal ataxia and some 
papilledema-her brain was normal. We recorded 
her intracranial pressure continuously through the 
Scott cannula and then slowly drained the ventricles 
over a period of two or three days, as we always do 
before doing posterior fossa surgery in these people. 
We also recorded and checked the systemic arterial 
pressure from the catheter in the the radial artery. 
For very long periods of time, the patient had a CPP 
as low as 6 mm Hg, the mean intracranial pressure, 
85, and the mean arterial pressure, 91; this particular 
time, she was in the intensive care unit, sitting up 
reading a magazine, completely asymptomatic. This 
is an indication of the phenomenal degree of 
autoregulation that can be seen clinically. 
If a hypertonic solution such as mannitol has 
been given to a patient without causing reduction in 
his intracranial hypertension, we might conclude that 
mannitol has been of no benefit, and not give it to 
that patient again. We might say that the patient is 
refractory to mannitol. 
Often this is not the case, and the patient im-
proves despite no major ICP fall. How can this be? 
We postulate that mannitol has reduced edema. 
Reduction of the water content in the brain alone, 
obviously, should result in decrease in intracranial 
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pressure, but if one has compression of the microcir-
culation of the capillary bed in the venules by the 
edema, and one reduces the edema, what is going to 
happen to the cross-sectional area of the vascular 
bed? It will enlarge as the compression is relieved. 
Our guess is that as we remove the edema from the 
brain with the mannitol, the edema is being replaced 
by intra vascular blood secondary to expansion of the 
cerebral vascular bed. The net intracranial volume 
remains the same, and intracranial pressure does not 
decrease. What these data clearly show is that one 
cannot use intracranial pressure alone to determine 
whether or not mannitol nas had a beneficial effect on 
the patient; one must, unfortunately, measure CBF. 
The first indication for the use of mannitol 
therapy, in our opinion, is for reducing brain bulk 
during craniotomy, and second, for reducing ICP to 
permit time for emergency cerebral angiography. The 
third indication for its use is control of ICP during 
continuous recording of ICP. I believe that the inter-
mittent, or perhaps even the continuous, use of man-
nitol in these patients without continuous recording 
of intracranial pressure is very dangerous, because if 
the patient has a hemorrhage, a hematoma that is ex-
panding, reduction of the intracranial pressure causes 
further expansion of the hematoma; then, as the os-
motic gradient is reversed, fluid comes back into a 
space reduced by the enlargement of the hematoma. 
This kind of situation can kill the patient quickly. 
I will conclude by saying that I think the con-
tinuous measurement of intracranial pressure in the 
proper management of patients not only with severe 
head injuries, but with severe brain insults as well, 
has passed now from being a research tool to a virtual 
necessity. I cannot say the same thing, yet, about 
measurements of RCBF and cerebral metabolism, as 
we are now caught in an ethical bind. We have four 
or five RCBF runs, or consecutive studies, done on 
patients over several hours. Rarely have we been able 
to repeat these studies, because we did not feel justi-
fied in repuncturing the carotid artery, unless it was 
necessary to do an angiogram on the patient. My 
contention is that we would learn much more from 
one patient with severe brain injury who has ten CBF 
studies over a period of several days than we would 
learn from ten patients who have one study each. In 
order to prove that these techniques, which are ex-
pensive and time consuming, are really going to help 
us in the management of these patients, we now need 
to have a reliable noninvasive technique for doing 
RCBF. These techniques are now available, par-
ticularly in the form of either inhalation or in-
travenous injection of 138Xe, but the mathematics are 
extremely complex and must be done with a 
laboratory computer, but I think they are promising. 
In our neurosurgical intensive care unit, we are just 
beginning to compare the carotid injection of xenon 
with the inhalation of xenon, to see how well the 
results correspond in our patients with severe brain 
injuries. Ifwe obtain a reliable noninvasive technique 
and can repeat the RCBF studies every hour, day and 
night for as long as we wish, with no harm whatso-
ever to the patient, we will then be able to provide 
the intensive treatment for these patients and the 
evaluation of the therapy to which we have looked 
forward for so long. 
Continuous Intracranial Pressure 
Monitoring in Patients with Brain 
Injury: Technique and Application* 
JOHN K. VRIES, M.D. 
Assistant Professor of Neurosurgery, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University , Richmond 
In 1971, a twist drill technique for measuring in-
tracranial pressure (ICP) in patients with severe brain 
injuries was introduced at the Medical College of 
Virginia (1) . Shortly thereafter continuous ICP mon-
itoring utilizing the ventricular catheter technique 
of Lundberg was begun (2). It rapidly became 
evident that knowledge of the ICP in this group of 
patients speeded definitive diagnosis, provided an 
early warning of developing mass lesions before 
clinical signs appeared, and provided an objective 
assessment of therapy directed against brain edema; 
however, continuous monitoring by the Lundberg 
technique was cumbersome to perform and carried a 
significant risk of meningitis. In 1972, a new method 
of monitoring ICP was developed at our institution 
(3). The new method was based Cin the establishment 
of a fluid connection with the cerebral subarachnoid 
space by means of a special hollow screw. The 
technique proved much simpler and safer than the 
Lundberg technique. The development of this 
technique combined with the completion of a seven-
bed neurosurgical intensive care unit extended ICP 
monitoring to all patients at our institution with 
significant head injuries. The morbidity and mortality 
for severe head injury have steadily declined as the 
scope of patient monitoring has increased over the 
last three yeats. We now consider ICP monitoring an 
essential part of head injury management. 
* Presented by Dr. Vries at the 27th Annual Stoneburner Lec-
ture Series, February 8, 1974, at the Medical College of Virginia, 
Richmond. 
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Methods. Head injury patients are divided into 3 
categories upon arrival at the emergency room based 
on their level of consciousness. Patients who are coma-
tose upon arrival or patients with whom no verbal 
communication can be established are designated as 
severe (grade 3). Patients who are lethargic, but with 
whom verbal communication can be established, are 
classified as moderate (grade 2) . Patients who are 
fully awake are classified as mild (grade 1 ). The pres-
ence of any focal neurologic signs increases the se-
verity by one grade. 
Grade 3 patients have an immediate twist drill 
ICP measurement. A twist drill hole three-sixteenths 
of an inch in diameter is made at the level of the cor-
onal suture under local anesthesia . A ventricular tap 
is then performed with an 18 gauge blunt ventricular 
needle. ICP is measured by connecting the needle to a 
water manometer. After obtaining the ICP, 5-10 cc 
of air are exchanged into the ventricles and a brow-up 
ventriculogram is obtained to assess shift of the 
midline structures, Further management of these 
patients is based on the results of this examination . If 
the ICP is greater than 10 mm Hg and the midline 
structures are shifted, the patient is given 1 gtn/ kg of 
mannitol and is taken to the operating room for an 
exploratory craniotomy. If the ICP is greater than 10 
mm Hg and the midline structures are not shifted, the 
patient is taken to the angiographic suite for 
angiography. If the ICP is below 10 mm Hg and the 
midline structures are not shifted, the patient is 
taken to the intensive care unit and an elective 
angiogram is obtained. Continuous ICP monitoring 
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is performed on all grade 3 patients after they arrive 
at the intensive care unit. 
Grade 2 patients are taken to the angiographic 
suite for immediate angiography. If a surgical mass 
lesion is discovered, the patient receives l gm/kg of 
mannitol and is taken to the operating room for a 
craniotomy. If no surgical mass lesion is found, the 
patient is taken to the intensive care unit. Continuous 
ICP monitoring is performed in all grade 2 patients 
after they arrive at the intensive care unit. 
Grade I patients are admitted for close observa-
tion. If any clinical deterioration is noted, they are 
managed like grade 2 patients. 
Continuous ICP monitoring is performed by 
means of a special hollow screw which permits fluid 
contact to be made with the cerebral arachnoid space. 
The screw is shown in Figure I. The screw is inserted 
by threading it into the skull through a one-fourth-
inch twist drill hole, after the dura has been removed 
with a small angled curette under direct vision. This is 
illustrated in Figure 2. ICP is monitored by connec-
ting the lumen of the screw to a transducer by means 
of saline-filled tubing. The screw is shown in place in 
the x-ray of a postoperative patient in Figure 3. A 
typical ICP record, along with the blood pressure, 
central venous pressure, and EKG, is shown in Figure 
4. The ICP is displayed at each bedside on a wall 
mounted oscilloscope, and it is written out at a cen-
tral station on a strip chart for a permanent record. 
A maximum effort is made in grade 3 patients, 
after they arrive at the intensive care unit, to keep the 
important systemic physiologic parameters within 
normal ranges. All patients in this grade are placed 
on a regimen of thorazine, 25 mg IM every 6 hours, 
to help accomplish this. All patients in this category 
have endotracheal tubes or tracheostomies. They are 
placed on volume respirators and nursed in the level 
position on heat exchange mattresses. On this 
regimen, blood pressure can usually be adjusted by 
raising or lowering the head of the bed, blood gases 
and pH can be regulated by adjusting the respirator, 
and the temperature is easily regulated with the heat 
exchange mattress. 
Patients who have progressive brain edema, 
manifested by a steadily rising ICP after correction of 
any systemic abnormalities, in whom surgical mass 
lesion has been ruled out angiographically, are 
treated with ventriculostomy drainage and hyperven-
tilation to a Pco, of 25 mm/Hg. If this fails to control 
the ICP, the patient is cooled to 30°C. If ICP still 
cannot be controlled, a mannitol infusion at a rate of 
Fig. I 
0.1-0.3 gm/ kg/ hr is begun provided the serum os-
molarity does not exceed 320 mOsm/ L (4). 
Results. In 1973, twist drill I CP measurement 
and ventriculogram were used in 96 grade 3 head 
trauma patients to establish a working diagnosis. On 
only one occasion was there failure to tap the ventri-
_cle. There were no recognizable complications related 
to the procedure. The average time required to per-
form the procedure was 10-15 minutes including the 
taking of x-rays. Fifty-eight of the 96 patients had 
elevated ICP and a shift of the ventricular system. All 
58 patients had a surgical mass lesion confirmed at 
operation. Eleven patients had normal ICP and a 
midline ventricular system. None of these patients 
developed a surgical mass lesion. Twenty-seven 
Dura 
Subarachnoid 
space 
Pia 
Fig. 2 
176 VRIES: CONTINUOUS INTRACRANIAL PRESSURE MONITORING 
Fig. 3 
patients had elevated ICP and a midline ventricular 
system. Twenty-six of the 27 did not have surgical 
mass lesions by angiography. One patient in this 
group had an acute subdural hematoma on one side 
and a brain contusion with edema on the other side, 
giving him elevated ICP but a midline ventricular 
system. 
Since November 1972, ICP monitoring using the 
hollow screw technique has been performed 161 
times. It has been performed 102 times for head 
trauma. In the vast majority of cases, a satisfactory 
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recording of the ICP has been obtained, manifested 
by a good wave form on the oscilloscope trace. The 
average patient was monitored for seven days. The 
complications to date consist of four patients with 
superficial scalp infections, requiring local debride-
ment, one CSF leak, requiring revision of a scalp inci-
sion, and one subdural hematoma, which occurred in 
a patient who developed a bleeding disorder after in-
sertion of the monitor. 
The ICP monitor provided warning of develop-
ing mass lesions in all cases where such lesions 
developed. Even though grade 3 patients were heavily 
sedated, which tended to obscure the clinical picture, 
no case of unsuspected mass lesion occurred. The use 
of high doses of morphine and thorazine made the 
management of the group 3 patients much easier. 
Problems of temperature control, severe hyperven-
tilation on a neurogenic basis, and erratic blood 
pressure swings, for the most part, were eliminated. 
With improved control of systemic physiologic 
parameters, the need to resort to special regimens for 
the control of progressively increasing intracranial 
pressure was obviated. In 1972, 18 of these regimens 
were employed. In 1973, only one regimen was 
employed, even though more grade 3 patients were 
seen in 1973 than in 1972. 
Discussion. Twist driil ICP measurement and 
ventriculograni appear to significantly speed the 
definitive diagnosis and treatment of severe head in-
jury patients in the emergency room. The procedure 
had a high accuracy for differentiating betwe«n sur-
gical and nonsurgical mass lesion. It can be ac-
complished in 10-15 minutes, which is much faster 
than an angiogram under the best of circumstances. 
It is easy to perform in the patient with multiple 
trauma, because it does not require that the patient 
be moved or transported to an angiographic suite. 
Moreover, in some grade 3 patients, it is safer 
because it does not require the degree of patient 
restraint and positioning that an angiogram requires 
which may produce jugular compression, or airway 
obstruction. 
Continuous ICP monitoring using the hollow 
screw technique has proven itself simple, safe, and 
reliable. The obvious advantage of continuous ICP 
monitoring is to provide early warning of developing 
mass lesions before clinical signs appear and to assess 
the effectiveness of therapy directed at brain edema. 
Its most important use, however, may be that it per-
mits the use of depressant medications in these 
patients. Many of these patients have a marked 
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tendency toward hyperthermia, severe hyperventila-
tion, and erratic blood pressure swings. These 
tendencies can be most difficult to control with con-
ventional treatment regimens. By sedating these 
patients, however, it is easy to override these tenden-
cies with a respirator, a simple heat exchange mat-
tress, and patient positioning. In many of these 
patients, all of the intracranial compensatory 
mechanisms for the maintenance of brain metabolism 
have been maximally taxed. These patients cannot 
tolerate the additional stress of disordered systemic 
physiology. At the present time, we try to hold our 
severe head injury patients within the following 
physiologic limits: cerebral perfusion pressure (blood 
pressure-intracranial pressure) 75 mm Hg ± 10 mm 
Hg; P0 85 mm Hg± 15 mm Hg; Pco 30mm Hg± 5 
mm Hg; pH 7.4 ± 0.1; temperature 2 37° C ± 1° C; 
sodium 140 ± 5; hematocrit 35 ± 5. Our preliminary 
data seem to indicate that if this is accomplished and 
if it is combined with rapid diagnosis and treatment 
of surgical mass lesions, most cases of progressive 
brain swelling can be prevented. At the present time, 
a prospective study of this regimen in head injury 
patients is underway at the Medical College of 
Virginia. 
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N euro-Ophthalmology 1n Severe 
Head Injury* 
JOHN W. HARBISON, M.D. 
Associate Professor, Department of Neurology, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond 
If asked what the significance of neuro-
ophthalmology is in the evaluation of severe head in-
jury, many medical and surgical practitioners of 
neurology would promptly reply that it consists of 
monitoring pupillary reactivity in anticipation of 
the uncal herniation syndrome. A discussion of two 
broad premises of a factual nature, however, should 
easily convince these same practitioners that the 
neuro-ophthalmic evaluation of patients with severe 
head injuries offers far more than the Hutchinson 
pupil. 
Anatomically, the substrate of the eye-brain 
mechanism is prodigious. It includes every cerebral 
lobe, the basal ganglia, all divisions of the brainstem, 
the cerebellum, half of the cranial nerves, and one-
third of the spinal cord. The eye-brain mechanism 
can be involved or interrupted at virtually any level of 
the neuraxis. The resultant signs and symptoms 
provide a kaleidoscope of pupillary abnormalities, 
ocular motor disturbances of a peripheral and central 
nature, and visual disturbances ranging from impair-
ment or loss of acuity and field to complex perceptual 
and associative visual disturbances. 
The second factual premise is the extent of the 
head injury problem. Six percent of all disabling in-
juries involve the head. Automobile accidents, but 
one aspect of trauma, have a 66% incidence of head 
injuries. Within the American population at large, it 
is calculated that one person in two hundred will re-
quire medical care for head injury each year. Given 
* Presented by Dr. Harbison at the 27th Annual Stoneburner 
Lecture Series, February 8, 1974, at the Medical College of 
Virginia, Richmond. 
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the anatomic extent of the eye-brain mechanism and 
the magnitude of the head injury problem, the in-
cidence and variety of the neuro-ophthalmic signs and 
symptoms of head injuries become mind boggling. 
What can the neuro-ophthalmic aspect of head in-
juries provide in terms of patient evaluation and care? 
In the initial evaluation of any head injury. vic-
tim, a thorough neuro-ophthalmic examination will 
provide important clues to localization of sites of 
trauma, whether they are primary or secondary, 
direct or remote effects. Analysis of this information 
will facilitate diagnosis and prompt, proper therapy 
can be instituted. Despite these efforts, however, a 
number of neuro-ophthalmic sequelae of head injury 
will remain for the patient to recognize as he recovers 
from more serious aspects of the head injury. Many 
of the neuro-ophthalmic symptoms and signs 
demonstrated go beyond simple signposts in direct-
ing diagnostic considerations, investigations, and 
therapeutic endeavor. They serve a significant role in 
prognostication of the patient's course and residual 
neurologic and neuro-ophthalmic handicap. The 
neuro-ophthalmic evaluation must not be limited to 
the initial patient evaluation which may be not only 
remarkably hectic but may also be restricted by 
aspects of the trauma that either prevent adequate 
evaluation or are of such a nature that they are life-
threatening and preclude neuro-ophthalmic evalua-
tion. The neuro-ophthalmic examination should be 
repeated at clinically appropriate points during the 
hospital course and should be utilized as a monitor 
for following the patient's long-term progress. 
The value of the neuro-ophthalmic aspects of 
trauma are not restricted to the primary care of the 
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patient. Suitable documentation of the neuro-
ophthalmic examination can be utilized during the 
primary patient care and follow-up as a tool in 
achieving a better understanding of the basic 
mechanisms of brain injury. During recent years at 
the Medical College of Virginia, close cooperation 
between neurosurgery and neuro-ophthalmology has 
provided the opportunity to implement this concept. 
We are presently compiling data, helpful not only 
in primary patient care but also in understanding the 
basic mechanism of brain injury. 
The broad extent of the neuro-ophthalmic 
aspects of brain injury has been emphasized but space 
prohibits comprehensive discussion of its full range. 
An attempt, therefore, will be made to illustrate 
selected aspects of the neuro-ophthalmic conse-
quence of brain injury which may be both of interest 
and benefit. 
An appropriate beginning to the discussion of 
neuro-ophthalmic consequences of trauma is the con-
sideration of the concept of preexisting brain disease 
as a precursor to trauma. Eyster clearly explained 
that minor head trauma in the presence of basal in-
tracranial tumors may well produce unexpected 
neuro-ophthalmic signs of an oculomotor nature. 
Other neuro-ophthalmic signs can be produced by 
trauma and appropriately situated tumors. It is also 
clear that previously undiagnosed intracranial 
pathology may increase a patient's vulnerability to 
traumatic incidents. In a similar vein preexisting signs 
of a neuro-ophthalmic nature, either recognized or 
unknown, though unrelated and clearly independent 
of the traumatic incident, may cause significant 
diagnostic consternation. 
In introducing the topic, neuro-ophthalmology 
of severe head injury, it was noted that perhaps the 
most commonly sought neuro-ophthalmic sign of 
trauma was a pupillary abnormality. The abnormality 
most feared is the Hutchinson pupil-the dilation 
of the pupil ipsilateral to a mass lesion, producing 
transtentorial uncal herniation with third nerve im-
pingement. It is generally an evolving sign, although 
it may be present by the time of the patient's initial 
medical attention. Because of its sinister import, it 
must be differentiated from a similar pupillary abnor-
mality-traumatic mydriasis. 
Patients with severe head injuries also frequent-
ly receive direct blows to the eye. With direct blows to 
the globe, contusion of the iris may occur which 
results in a dilated and fixed pupil, usually unilateral-
ly. If seen early, the initial response to the contusion 
will be miosis; dilation and iridoplegia follow within 
minutes, however, and may last minutes, hours, days, 
or may be permanent. Often other signs of periorbital 
trauma will point to the correct diagnosis of 
traumatic mydriasis. In selected cases, however, it 
may be impossible to differentiate a Hutchinson pupil 
from traumatic mydriasis. In these situations in-
vestigations to rule out the transtentorial herniation 
syndrome are imperative. 
Oculomotor nerve palsies in head trauma are 
common; they are also significant parameters for 
localization and valuable monitors of the evolution 
of the trauma patient's course. Their diagnosis is 
most difficult in the comatose patient. In this situa-
tion, the third nerve paralysis is most easily 
recognizable, basically, because of the prominent 
features ofptosis, mydriasis, and generally prominent 
deviation of the eye downward and outward. Sixth 
nerve palsies are less readily documented and fourth 
nerve palsies are almost never recognizable in the 
presence of coma. The oculomotor evaluation in . 
comatose patients, however, is facilitated with the use 
of doll's head phenomenon and caloric responses. 
Differentiation of primary and secondary palsies is of 
great practical significance to the physician responsi-
ble for the care of the trauma patient. Oculomotor 
palsies, as primary traumatic injuries, are almost 
always present immediately. Secondary palsies, 
reflecting an evolving intracranial mass, generally oc-
cur many minutes to hours or days later. If the 
trauma patient is delayed in receiving medical atten-
tion, or if the initial examination is incomplete, this 
differentiation may not be possible. 
Clearly, early and accurate evaluation and 
documentation of ocular motility, as well as its con-
tinued monitoring during the patient's recovery, is 
important. The ophthalmologist, who must common-
ly deal with the motility disturbance at a time distant 
from the injury, may be extremely dependent upon 
this documentation for his analysis and decision 
regarding surgery of the paretic muscle. It is currently 
recommended that surgery on paretic muscles be per-
formed at any point after the fourth month, if max-
imal improvement has occurred. Statistics on the in-
cidence of oculomotor involvement in trauma are less 
reliable than is desirable, due largely to misdiagnosis. 
Involvement of the third and sixth cranial nerves is 
probably neady eqµally common. Fourth nerve in-
jury is distinctly less common. 
Third cranial nerve palsies are the result of 
significant frontal injuries generally associated with 
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concussion and skull fracture; they may be isolated 
sequelae of trauma. The site of third nerve injury is 
probably at its point of ·dural penetration at the 
posterior aspect of the cavernous sinus. The 
mechanism of injury is probably by virtue of shearing 
and stretching forces exerted upon the nerve with 
movement of the brainstem and skull base. 
Traumatic third nerve palsy is almost always uni-
lateral, bilateral involvement being so rare as to 
suggest an additional pathologic process. Aberrant 
reinnervation is common in traumatic third nerve 
palsy and generally becomes evident at two-to-three 
months after injury. Lid and pupil signs are easily 
recognized. 
Although fourth nerve palsy is less common 
than third and sixth nerve injury, it is by no means 
rare. It is easily missed. Fourth nerve involvement is 
often bilateral. Usually, it is the result of a vertex or 
frontal blow in which the dorsal midbrain and 
anterior medullary velum are contused on the ten-
torium. Motorcycle accidents are the common in-
citing event and permanent dysfunction is not un-
common. 
Sixth nerve palsies commonly occur with frontal 
blows; they may be bilateral and, if the mode of onset 
is unknown or not documented, it may be impossible 
to differentiate direct injury of the sixth nerve from 
the secondary effects of increased intracranial 
pressure. Injuries producing sixth nerve paralysis 
may be based upon the presence of petrous ridge frac-
tures. In this circumstance, associated paralysis of the 
seventh and eighth cranial nerve is common. 
Injuries producing fractures of the superior or-
bital fissure frequently result in combined in-
volvements of the third, fourth, and sixth cranial 
nerve. Such injuries have associated optic nerve in-
jury and visual loss 50% of the time. Trigeminal and 
facial nerve injury occur an additional 25% of the 
time. 
Frontal and superior orbital fractures may be 
associated with ptosis and elevator palsy due to 
paresis of the superior rectus. Although this is the 
superior division of the third nerve, it indicates in-
volvement at a different site-within the orbit. 
Associated involvement of the superior oblique as 
well as the optic nerve may occur. 
Also to be distinguished from true third nerve in-
jury is the elevator palsy caused by the incarceration 
of the inferior rectus in "trapdoor" fractures of the 
orbital floor. This, as part of the orbital blow-out 
fracture syndrome, is usually associated with 
enophthalmos and sensory loss in the distribution of 
the inferior orbital nerve. 
Supra- and internuclear ophthalmoplegia, from 
brainstem contusion on the free edge of the tentorium 
or from other less clear mechanisms, may be con-
fused with partial third nerve injury. Their 
characteristic appearance and a knowledge that they 
may occur will usually avoid confusion. 
The presence of a congenital Duane's retraction 
syndrome may cause confusion by its resemblance to 
a traumatic sixth nerve injury. Past history and the 
characteristic refraction of the globe with associated 
narrowing of the palpebral fissure on adduction will 
usually assist in the distinction. In a comatose 
patient, differentiation may not be possible. 
The presence of obvious evidence of local orbital 
injury will generally suffice to distinguish oculomo-
tor palsies of myogenic origin based upon local 
hemorrhage, contusion, and laceration of muscle. 
Obviously they may coexist with nerve injuries and 
their separation may be impossible. 
Finally, one must recognize that skew deviation 
and wandering, dysconjugate eye movements are 
common in the coma of concussion. They are felt to 
represent disruption of oculomotor integration by the 
same mechanism responsible for the alteration of 
consciousness-physiologic alteration of the reticular 
formation. With return of consciousness, oculomotor 
function also returns to normal. 
That blindness-visual loss-is a common result 
of head injury, is reflected in a quotation attributed to 
Hippocrates: "Dimness of vision occurs in injuries to 
the brow and in those placed slightly above." Visual 
loss can occur at any point in the visual pathways. It 
is most commonly encountered, if we exclude the eye 
itself, at the beginning and end of the intracranial 
pathways-the optic nerve and the occipital cortex. 
The differentiation of optic nerve and cortical 
blindness is seldom a problem. The exact definition of 
the mechanism of visual loss in both may be difficult 
yet extremely important. 
The mechanism of optic nerve injury is varied. 
Generally, the blow is severe but may be extremely 
mild. The site of injury is most frequently the optic 
foramen, with involvement of contiguous orbital and 
intracranial optic nerve. Despite this localization, x-
rays are seldom helpful. If visual loss is immediate 
and severe, the mechanism is likely to have been tear-
ing, nerve hemorrhage, or contusion necrosis. If 
the onset has been delayed minutes-to-hours, 
hemorrhage into the vaginal sheaths, secondary 
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edema or vascular compromise may be responsible. It 
is important to separate these two presentations since 
delayed visual loss may indicate a situation reversible 
by decompressive surgery. Immediate visual loss is 
virtually never remediable by surgical decompres-
sion. Unfortunately, the time of onset of visual im-
pairment is frequently clouded by unconsciousness. 
Spontaneous recovery, if it is to occur, usually will do 
so in a few days. Significant residual is the rule. 
Another mechanism of optic nerve and chiasm 
involvement in trauma is the compression of the 
nerve and chiasm against the sphenoid bone by the 
posterior orbital convolutions. The gyri recti may ac-
tually shift into the anterior chiasmal angle. 
Resulting visual loss with central scotomas or bitem-
poral field defects may not be recognized by virtue of 
altered consciousness. This syndrome is frequently 
associated with diabetes insipidus. 
Cortical blindness results basically from two 
mechanisms-direct injury to the occipital cortex and 
infarction secondary to vascular compromise by 
the transtentorial herniation syndrome. Cortical 
blindness is a frequent result of a direct blow to the 
occiput. The resulting blindness is seldom permanent 
and usually resoives in minutes, hours, or days. 
Although recovery is often complete, residual visual 
field defects may occur. When they do, they are 
homonymous and frequently consist of congruous 
paracentral scotomas. 
While compression of the third netve is well 
recognized in transtentorial herniation of the medial 
temporal Jobe with asymmetric supratentorial 
traumatic mass effects, compression or "pinching" of 
the posterior cerebral arteries with infarction of 
calcarine cortex is not. The resultant homonymdus 
hemianopsia or cortical blindness is infrequently 
recognized because, again, there is usually coma. If 
the homonymous defect is recognized, it is of 
lateralizing value as it almost always occurs on the 
side of the mass effect. Most commonly, they are first 
recognized if and when the patient recovers. 
The funduscopic examination in patients with 
severe head injuries may reveal pathology of 
diagnostic value. Several factors enhance the ex-
aminer's opportunity to obtain a satisfactory and 
relatively complete evaluation of the patient's fundus. 
Pupillary dilation may make the difference between 
an adequate exam and complete failure to visualize 
the fundus. Obviously, the decision to dilate the pupil 
of a head-injured patient must not be taken lightly 
and will depend upon a variety of factors. With the 
utilization of modern methods of evaluation and in-
tracranial monitoring, an appropriate dilated ex-
amination is more feasible. It remains imperative to 
note on the patient's bed and chatt what has been 
done and when. Another invaluable factor is ade-
quate illumination-a bright light. 
Papilledema, previously felt to be relatively un-
common in closed head injury, may occur far more 
frequently than suspected in a mild form _lasting 
several days. Occasionally, hidden globe perforation 
may occur, resulting in hypotony-low intraocular 
tension. This may produce disc edema. The syndrome 
will be unilateral. 
The appearance of preretinal hemorrhages in the 
fundus of a head-injured adult usually reflects a 
severe head injury with significant subarachnoid 
blood. The presence of a hemorrhagic retinopathy 
with prominent preretinal hemorrhages in an infant 
suggests several possible causes, the most prominent 
of which is the presence of subdural hematomas. It 
has been estimated that one-half of infants with sub-
dural hematomas have intraocular hemorrhages. 
Their significance is that they are relatively unrelated 
to the severity of the infant's presenting symptoms. 
The child may appear only mildly ill yet harbor sub-
durals. The association of subdurals with the battered 
baby syndrome gives the fundus picture of preretinal 
hemorrhages added significance. The severity of the 
preretinal hemorrhages is highly variable; severe 
hemorrhage is common, however, and on occasion 
may fill the vitreous. Their presence is generally 
bilateral. The prognosis is also variable. In extreme 
cases, fibrosis may occur with traction and retinal 
detachment. They most frequently clear without 
significant residual. 
Commotio retinae or retinal contusion results 
from severe direct blows to the globe itself. Abrupt 
rises in intraocular pressure occur, with distortion 
and shearing forces affecting intraocular structures. 
The resulting contusion necrosis with cloudy gray 
swelling, usually affecting the maculae and posterior 
pole, generally culminates in severe permanent visual 
impairment. 
Many patients with severe head injuries suffer 
additional trauma to other parts of the body. Specific 
types of injuries result in characteristic retinal 
pictures. 
In compression or crushing chest injuries, the 
resulting increased intravascular pressure is 
transmitted to the eye producing a specific fundus 
picture-Purtscher's retinopathy or traumatic retinal 
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angiopathy. This consists of multiple superficial 
cotton-wool spots, of one disc diameter or less in size, 
generally located in the posterior pole between 
arterioles and veins. Associated retinal and preretinal 
hemorrhages are the rule. Initial visual impairment is 
variable but usually significant. The fundus picture 
may be delayeq two-to-three days. The course is 
usually one of progressive return to normal over 
weeks to several months. 
The occurrence of retinal fat emboli in fractures 
of long bones is frequently overlooked since the 
patients are either comatose or have no visual symp-
toms. The retinal picture consists of several small 
cotton-wool exµdates, usually but not invariably, 
fringed by hemorrhage as well as additional retinal 
hemorrhages which usually occur in the posterior 
pole but seldom affect vision. The presence of the 
better known aspects of fat embolization should 
facilitate their recognition. 
In closing, a single classic and nearly diagnostic 
external neuro-ophthalmic sign in head injury might 
be mentioned. This is the so-called "panda sign" of 
bilateral orbital ecchymosis restricted by the 
palpebral fascia to the orbital margin resulting in its 
nearly circular configuration. Its characteristic 
purplish color and commonly delayed appearance of 
two-to-three days are strong evidence of an anterior 
cranial fossa fracture. 
Advances 1n N euroradiology* 
FREDERICK S. VINES, M.D. 
Associate Professor of Radiology and Neurology; 
Chief, Section of Neuroradiology, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond 
CHARLES BONSTELLE, M.D. 
Assistant Professor of Radiology, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond 
The development of two new radiological 
techniques has significantly enhanced the perform-
ance of neuroradiological diagnostic procedures. 
The first of these was installed as the prototype unit 
at the Medical College of Virginia in November of 
1972 and has marked advantages for the performance 
of encephalography, angiography, and air mye-
lography. The present communication will relate 
the experiences of the author during the initial 15 
months of clinical evaluation. The second technique 
is an entirely new concept of obtaining further infor-
mation from the data provided by the penetration of 
x-ray photons. Each of these units will be discussed 
briefly with an outline of the principle indications and 
advantages of each system. 
An lsocentric Diagnostic System. The principle 
feature of this system is a fully isocentric unit (Om-
nitomet) maintaining the head in alignment for film-
ing or fluoroscopy, regardless of the patient's posi-
tion during 480° of continuous rotation (Fig. 1 ). AC-
arm rotates 300° about the isocenter. The L-arm 
provides 270° of rotation parallel to the wall axis 
with consequent alteration in the site of rotation of 
• Presented by Dr. Vines at the 27th Annual Stoneburner Lec-
ture Series, February 8, 1974, at the Medical College of Virginia, 
Richmond. 
t General Electric Corporation, Medical Systell)s Division, 
Milwaukee, Wisconsin . 
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the C-arm. This unit was designed primarily for 
pneumoencephalography and enables one to obtain 
standard film series as well as Gtossmart tomography 
in the frontal or lateral views, as indicated, regardless 
of the patient's position. A unique feature is the ability 
to perform tomography at varying angles of in-
cidence (Fig. 1-B). The brain stem may be 
tomographed coronally, therefore, relative to its ver-
tical alignment and areas such as the temporal horns 
or corpus collosum may be viewed perpendicularly to 
their long axis without movement of the head and 
subsequent alteration in the position of the contrast 
material. There is lateral, longitudinal, and vertical 
adjustment of the chair relative to the isocenter, so 
that once the isocenter has been established, the 
patient may be moved to readjust as necessary 
throughout the procedure. An image intensifier and 
television system are incorporated into the C-arm, 
allowing constant fluoroscopy regardless of the pa-
tient's position. The Omnitome system is also 
equipped with a phototimed 105 mm camera 
providing for either single or multiple frame, up to 12 
per second, with fluoroscopic control. The unit may 
be operated from the remote control panel or a 
mobile hand control may be utilized with closer 
observation of the patient. Television monitors are 
available iii the control booth and adjacent to the 
patient. The usual encephalogram includes standard 
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Fig. IA. Fig. IB. 
Fig. l-Omnitome-C-arm-1; L-arm-2 A. Patient positioned for erect frontal views. B. Position for erect frontal view with L-arm angled. C. 
Prone, A-P view. D. Normal lateral encephalogram tomogram . E. Coronal tomogram of right acoustic neuroma. Fourth ventricle (4) com-
pressed and rotated. F. Coronal tomogram I cm anterior to E with mass adjacent to pons. 
films in the erect and supine position with the 
remainder of the film series obtained on the 
photospot camera. This enables one to obtain multi-
ple different projections and angulations with a 
significant reduction in the time required to perform 
Fig. IC. 
the study. Both filming and positioning are done with 
fl.uoroscopy, obviating the time required for changing 
film cassettes. 
An accessory table is utilized for air mye-
lography on the Omnitome (Fig. 2). The technique 
Fig. ID. 
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Fig. IE. 
emphasized by Heinz (I) has been used primarily 
for study of the cervical spine. This technique is 
usually utilized for patients with cervical fractures or 
cervical spondylosis. Unstable cervical spine frac-
tures are ideally suited for this study, allowing one to 
maintain adequate skeletal fixation with the patient 
supine. Degenerative disease of the cervical spine is 
also well studied by this method, since the surfaces of 
the spinal cord can be evaluated with tomography as 
well as the ventral defects associated with 
degenerative cervical discs. A lateral puncture of the 
subarachnoid space is quite easily performed under 
fluoroscopic control at the Cl-2 interspace. Filling of 
the entire subarachnoid space is obtained with the 
patient supine and in 20° Trendelenberg position. 
Fig. 2A-Patient positioned for air myelogram in 20° 
Trendelenberg. 
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Fig. IF. 
The accessory table is also utilized for 
angiographic procedures, with the C-arm providing 
fluoroscopic versatility (Fig. 2-C). Vertical height ad-
justment of the table of 50 cm is available for 
magnification studies. The table top may be motor 
driven or converted into a free-floating surface with a 
foot switch. Adequate distance is available for 
femoral catheterization. Filming may be obtained on 
the 105 mm camera or with standard film changers. 
The 105 mm camera again is quite beneficial, 
providing the capability of a "see-through" changer 
with rapid serial filming available at all times during 
fluoroscopy. The ability is also preserved to perform 
multiple complex angle views rapidly. A second tube 
may be positioned on a floor pedestal for bi-plane 
filming if desired. 
The indications for angiography on this unit are 
necessarily determined by the availability of other 
angiographic facilities. The principle advantage of 
angiography on the Omni tome is the 105 mm camera, 
Fig. 2B-Normal lateral tomogram. 
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Fig. 2C-Positioning for angiography for serial film changers 
cephalad to patient. 
Fig. 2D-Right bracial injection (105 mm). 
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and therefore, cases are chosen where this would be 
of significant benefit. Patients studied for spon-
taneous subarachnoid hemorrhage or extracranial 
vascular disease are particularly suitable as are those 
patients requiring selective spinal cord angiography. 
Multiple views may be obtained with a significant 
reduction in time to perform the study and conse-
quent reduction in patient discomfort and com-
plications . The possibility of obtaining a standard 
film series in the optimal projection is available after 
preliminary study with the 105 mm camera . 
Angiotomography is also available as an ancillary 
procedure, since the C-arm maintains its ability to 
perform tomography wherever positioned. 
Supplementary benefits of this system are multi-
ple. One may obtain standard views of the skull or 
cervical spine utilizing the orbiting system and 
fluoroscopic centering. Obviously procedures requir-
ing bi-plane fiuoroscopy such as ventriculography, 
orbitography, or cerebral biopsies are simplified with 
this facility. 
Computerized Axial Tomography. The second 
portion of this discussion will involve a new tech-
nique that has been variously . compared with the 
discovery of penicillin or the first use of contrast 
material to complement standard radiographic 
techniques. Radiologi-sts have long recognized that 
less than 10% of the information available on stan-
dard radiographs is actually interpreted by the physi-
cian. This new technique utilized computer analysis 
of the x-ray photon transmission? making it possible 
to analyze physical properties of normal cerebral 
tissues and a wide variety of pathological lesions. 
The prototype equipment was installed in 1971 , 
the first clinical reports appearing in 1972 by James 
Ambrose at the British Institute of Radiology (2). 
Since his initial reports, others have confirmed the 
importance of this unit and its acceptance throughout 
the world has been universal (3) . 
The patient lies on an adjustable couch with his 
head enclosed in a cap projecting into a water con-
tained box (Fig. 3-A). He is comfortable, -fully 
dressed, and no additional contrast materials are 
necessary. A slit x-ray beam scans the head using the 
sodium iodide crystalphotomultiplier to detect the 
photons. The detectors move in parallel with the x-
ray tube across the patient's head with 160 readings 
of photon transmission during each horizontal move-
ment (Fig. 3-B). The entire frame then rotates one 
degree and the horizontal movement is repeated. For 
each parallel movement of the unit, therefore, 28,800 
VINES: ADVANCES IN NEURORADIOLOGY 187 
HEAD SUPPORT 
RUBBER HEAD BAG 
c 
:;~: 
-Blood 20 
Or-vMm• t8 
... 
300 
200 
WhlteMlltw 12 ... 
...... . 
• f at -SO 
-100 
-200 
-
_,.. 
Fig. 3-A. The EMI scanner. B. Rotation sequence of scanning unit. C. Patient positioned for tomograms to include orbits and posterior 
fossa. D. Arbitrary scale of absorption values with air as - 500 and water as 0. 
absorption readings are obtained, which the com-
puter can analyze within five-to-ten minutes . 
Routinely three or four axial sections are obtained 
with two scans of each slice. The head may be 
rotated to include the posterior fossa on the caudal 
scans if clinically indicated (Fig. 3-C). These are nor-
mally 13 mm by 2.94 mm by 2.94 mm, but an 8 
mm collimator may be used if desired. 
The data may be stored in two forms for recall 
when desired. A paper printout is available with 
numerical values of the relative absorption 
coefficients. There is also a cathode ray tube display 
of the information in an 80 by 80 matrix form . A 
Polaroid® camera is used for photographic records of 
the cathode ray tube display. 
The absorption values are a normal function of 
the physical density and the atomic numbers of the 
tissue analyzed. The relative absorption values are il-
lustrated in Figure 3-D. Water is used as a reference 
(i.e., water = 0) and the scale of relative percentage of 
absorption of intracranial tissues is expanded several 
times for convenience. Utilizing a gray scale picture 
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Fig. 4-Normal axial tomograms beginning caudally (A) and 
progressing superiorly. A . Caudal section . Broad white outer zone 
is the skull . Petrous temporal bone (p) and orbits (0). Fourth ven-
tricle is black area posteriorly (4). 
Fig. 48-Ambient, interpeduncular and sylvian (s) cisterns. 
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Fig. 4C-Frontal horns, third ventricle(!), and trigone of lateral 
ventricles. Pineal calcification behind third ventricle and glomus 
calcifications in trigone. 
of each tomographic section, water density would be 
black with increasing grayness-to-white at the bone 
level. It can be seen that water density is adequately 
separate and allows the basal cisterns and ventricular 
system to be visualized with ease (Fig. 4). Likewise, 
calcifications are very clearly delineated, such as in 
the pineal gland or glomus of the choroid plexus. It 
must be emphasized that this technique utilizing ab-
sorption coefficient differences and computer analysis 
is much superior to the previously used photographic 
methods and computer enhancement processing of 
photographic images. Preliminary data indicate that 
all of the cerebral tissue, cerebrospinal fluid, and 
coagulated blood are very easily distinguished. The 
matrix actually allows for analysis of individual 3 mm 
lesions at any point of each tomogram. 
The preliminary results obtained in this country 
have confirmed the reasons for the rapid acceptance 
of this dramatic new technique. The most striking 
pathological change is with an intracerebral 
hematoma (Fig. 5-A). The clotted blood is quite easily 
seen, with its absorption coefficient in the 20 to 30 
range, and extension into the ventricles or the cortex 
is easily delineated . Cerebral infarcts must be 
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Fig. 4D-Lateral ventricles. 
differentiated during their various pathological 
stages. The early lesion may be patchy with decreased 
absorption and much larger definition occurring in 
seven-to-ten days as the necrotic area becomes 
sharply defined with the onset of phagocytosis. 
Gliomas are highly variable not only from case 
to case, but in different parts of the same tumor (Fig. 
5-B). Cystic areas within the neoplasm may be seen 
by the decreased absorption with areas of more dense 
and compact tumor delineated by an increased ab-
sorption value. More importantly, one is able to 
evaluate deep infiltration of a portion of tumor into 
the critical deeper structures. 
Metastatic neoplasms tend to be more cir-
cumscribed than the primary gliomas (Fig. 5-C). The 
center may be necrotic and cavitated with a decreased 
absorption or may be dense and compact with a large 
surrounding area of cerebral edema and consequently 
with deer.eased absorption. 
The development of this procedure has sig-
nificantly altered the evaluation of. patients with 
cerebral dysfunction. One is now able to selectively 
choose which patients will require the more invasive 
but precise technique of pneumoencephalography 
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Fig. 4£-Lateral ventricles. 
Fig. 4F-Cortical sulci. 
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Fig. SA-Left thalamic hemorrhage (h) with frontal horn compres-
sion and shift. 
Fig. SB-Left frontal astrocytoma extending deep into basal 
ganglia. A large cyst (c) is also present. 
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Fig. SC-Deep right thalamic metastases with a cavitated center. 
and angiography. There will also be fewer negative 
results with these studies. The tomographic study 
enhances other techniques and will enable isotope 
brain scanning techniques to become more specific 
with the development of tissue specific radionuclides. 
The results from one center (3) indicate that of the 
first hundred patients that underwent computer as-
sisted tomography, 71 of them required one or more 
neuroradiological procedures for diagnosis. In the 
fifth group of 100, however, only 34 required further 
study. 
The expertise required to interpret this to-
mographic study is somewhat more than one would 
anticipate. One must not only interpret the patho-
physiological data, but he must also know the asso-
ciated features and types of mass effect created by 
different lesions. He must understand not only the oc-
currence of a glioma but its typical pattern and 
course of infiltration as well as the types of cerebral 
infarction and their sequential pathological develop-
ment in time. He must also know what pathological 
conditions are associated with cerebral edema or 
necrosis, and how this may modify the absorption 
values. Likewise, the initial feeling that differentia-
tion of the gray and white matter could be attained 
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with ease has been less commonly observed in prac·-
tice. The technical limitations in the evaluation of the 
base of the skull and particularly the cerebellopontine 
angles has been less impressive. Most investigators, 
however, have now shown that with care this area can 
be seen with certain limitations. Extracerebral he-
matomas were also considered to be a significant 
problem with the use of this unit. Extradural he-
matomas with their larger portion of congealed 
blood have easily been seen; however, subdural 
hematomas have varied considerably and require 
care of the observer in interpreting the results . Since 
the hematoma may be totally liquid and therefore of 
water density, the absorption may be considerably 
different from a hematoma that is mixed in character 
or contains more clotted blood and is more dense 
than the surrounding cortex. Frequently there is also 
adjacent cerebral edema which limits the exact 
differentiation between the borders of the hematoma 
and the cortex. Even with this limitation, however, it 
is considered that with careful evaluation of the edges 
of the lesion, the hematoma may be ascertained with 
a high degree of accuracy. Even if the hematoma is 
not delineated fully, the shift of the ventricular 
system and cerebral structures is quite easily seen and 
accurately indicates a source of the cerebral dysfunc-
tion. 
There is no question that the avenues for re-
search and further investigation available through 
this technique are unlimited. Most importantly it is a 
functional and clinically useful tool that can be per-
formed safely on inpatients or outpatients with no 
morbidity. The procedure may be conducted by an 
experienced neurotechnologist after a short period of 
familiarization with the method and equipment. The 
limitations of this technique are negligible in view of 
its outstanding advantages. There is clear indication 
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that there will be a significant reduction in the 
number of pneumoencephalograms, and in select 
cases, angiography will also be omitted from the. 
diagnostic evaluation. Carotid angiography will no 
longer be necessary to evaluate an intracerebral 
hematoma or hydrocephalus. Radionuclide brain 
scanning will have a limited place in the diagnostic 
evaluation. These are immediate benefits and only the 
future will ascertain the long-term alterations in the 
~valuation of patients with disease of the central ner-
vous system. 
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Advances 1n the Management of 
Pituitary Tumors* 
CHARLES B. WILSON, M.D. 
Professor and Chairman, Department of Neurosurgery, 
University of California, San Francisco 
A new development in the management of 
pituitary tumors is the transsphenoidal technique. It 
will be my purpose to show that it provides an elegant 
way of handling the great majority of pituitary 
problems, at least the ones that I have encountered, 
although it has its shortcomings as well as its 
advantages. 
Pituitary tumors manifest themselves in two 
ways-by compressing structures in the neigh-
borhood, primarily the optic nerves and chiasm 
and by the two endocrine manifestations, one being 
the compression of the normal pituitary gland to 
produce varying degrees of hypopituitarism and the 
other, the hyperfunctioning adenoma. A large tumor 
with a suprasellar extension compresses the optic 
chiasm and optic nerves; obviously, a tumor of this 
size would also cause a degree of hypopituitarism. A 
smaller tumor, a microadenoma, can express itself by 
hypersecretion of a hormone before it has either 
produced neighborhood signs or has compressed the 
normal gland to produce hypopituitarism. A func-
tioning microadenoma secretes an excess of a par-
ticular hormone; we have encountered three 
neoplastic cell types that I will describe later. 
We owe the transsphenoidal approach to Harvey 
Cushing, who took up the procedure because at that 
time it was safer than craniotomy. Dr. Cushing, 
working with a headlight (looking very much like a 
coal miner's lamp) and with a simple speculum, 
achieved excellent results. He encountered two 
problems-he was viewing a deep, dark hole without 
* This is an edited transcript of a lecture presented by Dr. 
Wilson at the 27th Annual Stoneburner Lecture Series, February 8, 
1974, at the Medical College of Virginia, Richmond. 
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magnification, and there was a CSF lead and 
meningitis without the advantage of antibiotics. A 
Frenchman, Guiot, is largely responsible for rein-
troducing the transsphenoidal procedure. One of his 
brilliant students, Jules Hardy, refined the technique, 
using the operating microscope and an image inten-
sifier, which allows the operator, during the 
procedure, to observe operative maneuvers in the 
region of the sella. 
The anatomical principles underlying the sur-
gical approach to the pituitary are really two: One is 
a sublabial-transnasal-transsphenoidal approach, 
maintaining the strict midline which is of great ad-
vantage to the surgeon, because he can see equally 
well to the right and to the left and he knows that he 
is in the midline. The second is the image intensifier in 
the lateral projection, because this permits the sur-
geon to look on the television monitor so that he can 
approach the sella between the tuberculum and the 
floor; he can see his instruments within the sella, and 
he can put air in the ventricul~r systein at the begin-
ning of the operation and watch the third ventricle 
pulsate down into its normal position as the 
suprasellar component of the tumor is removed. For 
maximum safety, the image intensifier is essential. 
With experience, one can see and identify the normal 
pituitary gland, and the surgeon can be certain that 
the suprasellar component has been removed, 
because the nortnal intracranial pressure in a semisit-
ting position forces the stretched diaphragm of the 
sella (which we have erroneously referred to as the 
tumor capsule in the past) back down into the sella, 
so that with a sizable suprasellar extension, one ac-
tually ends up with a diaphragm almost pulsating on 
the floor of the sella. 
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Dr. Hardy has recently ·suggested that mi-
croadenomas of certain cell types occur in pref-
erential sites within the anterior lobe. This has 
not been our experience, but his larger experience is 
more valid. The endocrinologists with their elegant 
techniques can pick up endocrinopathies at an early 
stage. Our neuroradiology had to improve to iden-
tify a microadenoma, when the endocrinopathy was 
defined. This is particularly true, not so much in 
acromegaly, but with the galactorrhea-amenorrhea 
syndrome and postadrenalectomy Nelson's syn-
drome. 
We are completing a paper on our experience 
with the neuroradiology of microadenomas. 
Although in the lateral projection, the sella is un-
remarkable, on plain films, lateral polytome cuts 
show an obviously abnormal sella. With A-P 
polytome cuts, one can predict the location of the 
microadenoma because of depression and thinning of 
the floor of the sella. The surgeon can expose the 
microadenoma at the site of the focal sellar bulging. 
A microadenoma is 1 cm or less in diameter. 
These small tumors are ideally suited to trans-
sphenoidal removal. One would not approach a 
microadenoma with the classical transfrontal tech-
nique, since it is difficult to reach and involves going 
through normal anterior pituitary at an awkward 
angle to reach the adenoma. 
I have removed 60 pituitary tumors by a 
transsphenoidal approach; one-half presented with 
hyperfunctioning adenomas. My experience with 
these tumors has pushed me strongly in two direc-
tions: First, we have an extremely active endocrine 
group and a large number of acromegalic patients; sec-
ond, I work with a neuro-ophthalmologist, William 
F. Hoyt, who attracts patients with unusual eye 
problems, a fair number of whom have pituitary dis-
orders. Approximately one-fourth ~f his patients had 
clinical and chemical hypopituitarism at the time of 
presentation-I I% complained of visual loss; 7%, of 
diplopia; 6%, of headache; and 4% had rhinorrhea. 
Regarding visual-field defects-58% had no de-
fect, 32% had bitemporal hemianopsia or some 
variation of that, and 10% had some other type of 
visual-field defect. 
By routine stains, 62% were chromophobe, 36% 
eosinophil, and 2% basophil. In the chromophobe 
group are some prolactin-secreting adenomas, some 
growth hormone-secreting adenomas, and some 
ACTH-secreting adenomas. According to functional 
types, 40% secreted nothing or, at least, nothing that 
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we recognized. I suspect, however, that this number 
would be smaller, if we checked every patient for 
prolactin levels, because elevated prolactin levels can 
exist without any overt clinical manifestation . The 
remaining 60% secreted an excess of one hormone: 
14% prolactin, 10% ACTH, and the remainder, 
growth hormone. All patients with ACTH-secreting 
tumors had undergone prior adrenalectomy and 
presented with hyper-pigmentation and high ACTH 
levels. 
With respect to anatomical extent of the tumors, 
33% were entirely intrasellar. Some of these were 
microadenomas; some were not. Even with very large 
sellas, the tumor may be contained within the sella. 
The remainder extended beyond the sella-some with 
extrasellar extension in more than one direc-
tion-42% were suprasellar, 28% had eccentric lateral 
extension, and 23% went into the sphenoidal 
sinus. The number of sphenoidal and suprasellar 
extensions is directly related to the quality of the 
neuroradiology. 
When we began using the transsphenoidal 
technique, we got only the castoffs-patients who 
had failed to respond to prior treatment. Ours was 
the second team in terms of handling pituitary 
problems, but as we demonstrated our ability to han-
dle recurrent tumors, we began seeing primary cases. 
As we gain greater experience with the acro-
megalic patients, we are reducing growth hormone 
levels down to very low levels, like 2-3 ng/ml. Not 
a single patient, primarily treated for acromegaly, 
. has developed hypopituitarism following opera-
tion. Transsphenoidal removal constitutes excellent 
treatment for acromegaly, and we are seeing more 
and more patients. We are in the process now 
of designing a study which will compare 
transsphenoidal removal alone with transsphenoidal 
removal plus irradiation. Unless postoperative 
growth hormone levels are in the normal range, the 
adenoma has not been removed. Because our ex-
perience is limited, we do not know how many of 
these patients will return with late recurrence. 
Patients with Nelson's syndrome have un-
dergone adrenalectomy for Cushing's disease, and at 
variable times thereafter, become hyperpigmented. 
Many tumors that secrete ACTH are malignant in 
the biologic behavior, which is a compelling reason to 
make the diagnosis and to treat them radically as 
soon as possible. 
One of the more interesting facets of the 
microadenoma story is the syndrome of galac-
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torrhea and amenorrhea. Historically, three 
types of galactorrhea and amenorrhea have 
been described, depending upon whether the syn-
drome appeared following delivery or spontaneously. 
The group of interest here is the Forbes-Albright syn-
drome, which can have its onset either postpartally 
or, more often, spontaneously. By definition, the sella 
turcica is enlarged, and galactorrhea and amenorrhea 
are permanent. The only difference between the 
Forbes-Albright and the Del Castillo syndrome is the 
normal sella, and here I think it is a matter of time. 
These patients have microadenomas, but until one 
studies the sella by polytomography, the sella may 
appear normal. We now have eight of these 
patients-three harbored macroadenomas and the 
remainder, microadenomas. These, like the ACTH-
secreting adenomas, have a greater liability than the 
usual chromophobe adenoma to become invasive. 
For some reason, unlike the growth hormone-
secreting adenomas or acromegaly, tumors that 
secrete prolactin and tumors that secrete ACTH are 
inherently bad actors; that is, they have a relatively 
high risk of becoming malignant as judged by in-
vasive behavior. 
Excluding one patient with an intrasellar 
abscess, we have had no operative deaths, and this is 
a significant advantage of the technique. We di-
vided the morbidity into major and minor, the ma-
jor including pneumonitis and rhinorrhea. If we think 
that the patient might be developing rhinorrhea, we 
treat vigorously in the first five postoperative days; I 
am certain that we are overtreating and unnecessarily 
treating a number of patients. We insert a lumbar 
subarachnoid drain, start Diamox®, and elevate the 
head; and our rhinorrhea rate falls very rapidly. Two 
patients had transient cranial nerve palsies due to 
vigorous use of a curette against the wall of an 
already compressed cavernous sinus. One patient had 
a postoperative hematoma within the tumor capsule. 
This was recognized within four hours, and the 
patient was returned to the operating room, where it 
was removed with no consequences. Five patients 
had diabetes insipid us persisting longer than a month 
and four patients had transient diabetes insipidus. An 
aseptic meningeal reaction from blood in the CSF, 
sinusitis, nose bleed, one corneal abrasion, and 
urinary tract infections represented minor com-
plications . In no patient who had either normal or 
impaired vision prior to operation was vision made 
worse; this makes it a very attractive procedure, 
because even with the very best results from the 
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transfrontal technique, vision was made worse in an 
occasional patient. 
The transsphenoidal technique is the procedure 
of choice under the following circumstances. 
l. Sphenoidal extension; 
2. Modest suprasellar extension without lateral 
extension: We can handle the direct upward 
suprasellar extension. In the last 18 months, I 
have operated on 40 pituitary tumors, only 
one of which was· done by craniotomy. There 
was a suprasellar extension that went laterally 
into one frontal lobe, and you simply cannot 
turn the corner going through the sphenoid 
sinus. Consequently, this patient was done 
transfrontally. 
3. The patient with paracentral, bitemporal 
scotomas: The neuro-ophthalmologist will 
assure you that this patient has either a pre-
fixed chiasm or a retrochiasmal nodule. 
This presents a difficult problem for the 
neurosurgeon operating transfrontally, be-
cause the optic nerves are hugging the 
tuberculum and there is no room to work 
between the optic nerves. This is, in my opi-
nion, an indication, unless there is some con-
traindication, to the transphenoidal route. 
4. The microadenoma (mentioned earlier); 
5. Spontaneous rhinorrhea in association with a 
pituitary tumor; 
6. Pituitary apoplexy : A low morbidity 
procedure accomplishes what you want to ac-
complish very quickly, and since these 
patients are often ill and need rapid decom-
pression, I think it is clearly the procedure of 
choice for pituitary apoplexy. 
7. The patient who is old or debilitated for 
whatever reason, or if you simply want to do 
a biopsy. 
Which tumors should be approached by the 
transfrontal technique? Again, this is my own preju-
dice. The massive suprasellar extension is a huge 
mass of intracranial tumor, and what is happening 
within and immediately above the sella is really not 
the important part of the tumor. I have discussed the 
tumor with lateral extension. Perhaps tumors with 
massive suprasellar and sphenoidal extensions should 
be removed sequentially by both routes . The one con-
traindication to any major procedure is unequivocal 
cavernous sinus invasion. Extraocular motor palsies 
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alone are not an indication of invasion. As pointed 
out by Sir Geoffrey Jefferson, a fixed sensory loss is 
the one clinical sign of cavernous sinus invasion. 
In summary, the one thing that is new in 
the management of pituitary tumors is the 
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transsphenoidal technique. Obviously, there still 
remains a place for transfrontal craniotomy and 
cryosurgery, but I predict that an increasing number 
of pituitary tumors will be done by the 
transsphenoidal technique. 
Advances 1n the Treatment of 
Patients with Benign Brain Tumors* 
HAROLD F. YOUNG, M.D. 
Associate Professor of Neurosurgery, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond 
Introduction. Since the Stoneburner Lecturer for 
this year, Dr. Thomas Langfitt, is Professor and 
Chairman at the hospital of the University of Penn-
sylvania, it would only be proper to recall at least one 
of the important lessons taught by Dr. Francis Grant, 
Dr. Langfitt's predecessor at the University of Penn-
sylvania. One of Dr. Grant's most remembered dic-
tums was that when a benign brain tumor is en-
countered, the best surgical team the clinic can 
assemble should be put to work on it (!). This is a 
valuable concept in the treatment of benign brain 
tumors. It is of paramount i.mportance to protect the 
brain, to preserve neurological function, to restore 
neurological function which has been lost, and to 
remove the tumor completely if possible. Ample 
statistics reveal a 20% recurrence rate in operated 
benign central nervous system tumors, a rate largely 
related to incomplete removal at the first operation 
(2). 
What are the recent advances which will ensure a 
better fate for the brain tumor patient? First is the 
diagnosis of the degree, if any, of increased in-
tracranial pressure (ICP) before surgery; second is the 
meticulous management of anesthesia at surgery; and 
third is the use of the operating microscope with the 
associated microneurosurgical instrumentation to 
provide magnification surgery. 
Intracranial Pressure. The recognition of in-
creased intracranial pressure is important not only in 
benign brain tumors but all brain tumors which 
*Presented by Dr. Young at the 27th Annual Stoneburner 
Lecture Series, February 8, 1974, at the Medical College of 
Virginia, Richmond. 
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manifest increased intracranial pressure by headache, 
altered states of consciousness, and the finding of 
papilledema. All brain tumor patients treated at 
MCV have ICP monitoring for three-to-five days 
before surgery, during surgery, and for at least three 
days following surgery with a subarachnoid screw (3). 
Figure l is a recording of intracranial pressure 
demonstrating increased intracranial pressure as the 
patient is being monitored before and during steroid 
treatment prior to surgery. 
If the baseline ICP is elevated above 40 mm Hg 
(normal less than 11 mm Hg), there will usually be 
plateau waves-a transient marked increase in ICP 
up to 60 Hg. With the rise in ICP or at the time of a 
plateau wave, there may be a decrease in the level of 
consciousness, hypoventilation, and an increase in Paco . 
The patient may then be aroused by severe headache~, 
or by an examiner, and may then hyperventilate, 
lowering the Paco , relieving the headache, and re-
turning intracrani~I pressure to the baseline. 
We have found, upon establishing the baseline 
ICP, that there is usually no rapid reduction of ICP in 
the first 24 hours of steroid therapy even though 
clinical improvement is seen during the same period. 
We have often observed a decrease in the number of 
plateau or Lundberg waves occurring in the first 
24-36 hours of steroid treatment. Early clinical im-
provement in the patient's condition, not associated 
with a lowering of mean ICP, may reflect a direct 
effect of steroids on the brain or improvement in 
cerebral blood flow as brain edema is reduced. 
Because ICP is usually reduced only after at least 
24-36 hours of steroids, all of our patients are 
prepar,ed for brain tumor surgery with three-to-five 
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days of steroids. During this long period of time, in 
which steroids may be necessary to reduce ICP, effect 
membrane stabilization and capillary integrity, they 
also may have a beneficial effect on other subcellular 
organelles such as lysosomes, which appear better 
preserved when the patient has been well prepared 
with steroids. Without steroids, under stress of 
trauma, breakdown of lysosomes results in formation 
of lipofuscin bodies and the release not only of acid 
phosphatases, but of other hydrolytic enzymes as well 
(4). Experimental evidence also reveals a decrease in 
the severity of the traumatized brain when treated 
with steroids (5); thus, we use ICP monitoring and 
long-term steroid administration prior to surgery to 
reduce ICP and to protect the brain from any trauma 
that may occur during surgery. 
Anesthesia. The next important aspect of the 
management of patients with benign brain tumors is 
induction of anesthesia. This is a most critical time 
for the patient. Even preoperative sedation can cause 
hypoventilation, blood gas changes, and alterations 
in intracranial pressure between the time the patient 
leaves the floor and the time he arrives in the 
operating room. All brain tumor patients undergoing 
surgery have intracranial pressure subarachnoid 
monitoring not only preoperatively but during the 
induction of anesthesia as well. Likewise, an arterial 
line from the patient's radial artery is connected to a 
4 channel Grass recorder, and end-expiratory C02 is 
measured on a capnograph. By this technique we 
have been able to confirm that there are many times 
during the induction of anesthesia when a change in 
ICP may occur (6). A rise in ICP may be hazardous 
for the patient if increased intracranial pressure is 
present at the induction of anesthesia. It is best to 
have knowledge of the intracranial pressure prior to 
the induction of anesthesia as hyperventilation or in-
travenous mannitol may be needed to reduce in-
tracranial pressure. For instance, while halothane is 
not a dangerous anesthetic, increasing its concentra-
tion quickly increases intracranial pressure. Figure 2 
shows the reduction of ICP when intravenous pen-
tothal is administered. This is in agreement with 
Shapiro's recent report showing that thiopental 
sodium, or pentobarbital, will reduce intracranial 
pressure (7). Ethane is an agent useful in lowering in-
tracranial pressure unless increased to a concentra-
tion of 4% or more. lntracranial pressure monitoring 
reveals a balanced barbiturate anesthetic to be a 
valuable anesthetic technique in brain tumor surgery. 
At the time of intubation, there is usually a brief 
DAY 2 
DAY 4 
DAYS 
!NTRACRANIAL PRESSURE WITH 
STEROID AOMINSTRATIDN 
3 
TIME (MINUTES) 
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Fig. 1-lntracranial pressure recording in mm Hg during 5 days of 
steroid (Decadron® 4 mg Im q6h} treatment. On day I and 2 
baseline ICP runs between 30-40 mm Hg with plateau waves up to 
60 mm Hg. Plateau waves disappear on day 3 but baseline ICP is 
only in normal range on the fifth day of treatment. 
increase in intracranial pressure associated with a 
small change in arterial blood pressure (Fig. 2) . A 
short period of straining on the endotracheal tube 
will likewise produce a rise in ICP, and prolonged 
straining or "bucking" must not be allowed. 
After the induction of anesthesia, the surgeon 
must carefully position the patient's head for his sur-
gical advantage without turning the head so severely 
that a major blood vessel to or from the head is 
occluded; this is often overlooked in preparing the 
patient for surgery. Care must be taken not to 
obstruct venous drainage from the head as this will 
certainly increase ICP. 
INTRACRANIAL PRESSURE AND BLOOD PRESSURE 
CHANGES AT ANESTHESIA INDUCTION 
(m~i:]••••• J.H. 23 y.o.mole l.:eft frontal glioma 
ic:or 
(mm.Hg~ 
1501 BP 
(mm.Hg~ 
601 \m~,~~ JTle \entilation 
scope out Anectine in 
Laryngoscope 
Fig. 2-(Top Tracing) Pentothal lowering ICP within l minute of 
administration; 50 mg pentothal produced a slight decrease in ICP 
while 350 mg produced a marked decrease in ICP. (Bottom Trac-
ing) Rise in ICP to almost 60 mm Hg during intubation. 
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Following the induction, both the surgeon and 
the anesthesiologist must also focus on ventilation of 
the patient. Figure 3 is the ICP recording of an opera-
tion on the posterior fossa where spontaneous 
respiration is generally used since it is a safeguard 
against undue trauma or traction of the bq1instem. 
Spontaneous respiration produced a prompt rise in 
intracranial pressure and the patient was then placed 
on a respirator to control ventilation and reduce ICP. 
In order to operate on an adult patient, intracranial 
pressure is maintained in a safe range witjl ventilation 
controlled at the rate of 12 respirations/ min and a 
tidal volume of 900 cc with each respiration . Unfor-
tunately, when the surgeon is operating he may, 
nevertheless, reach a point where he is about to open 
the dura only to find it very tight. If the surgeon 
demands that the anesthetist hyperventilate the 
patient, an over reaction by the anesthetist of rapid 
hand ventilation may result in exchange of a small 
tidal volume too rapidly for sufficient venous return 
and intracranial pressure may not be lowered but 
may actually be increased. The induction of 
anesthesia must be attended by the neurosurgeon as 
well as the anesthetist. This is one of the most impor-
tant aspects of the operation, errors in management 
of the anesthetic resulting in intracranial pressure 
changes could lead to a tragic result from the operation. 
Magnification Surgery. One of the reasons for 
emphasizing control of intracranial pressure and the 
induction of anesthesia is that it is important, in the 
technique of operating on a brain tumor using an 
operating microscope, to have as much ttxposure as 
possible often beneath the brain or deep within the 
SPONTANEOUS AND ASSISTED 
VENTILATION IN SURGERY 
E.8. 54 y.o. female 
Posterior fosso meningiomq 
B:ooI 
(mm. Ho~ ----------~------__,) 
(m~c~:] f 
Breothino;i 
spontaneously 
t 
P01125,PC0144 
pH 7.45 
"' ·r E(fired -V-V"----V..""""' :~~~ I-~~--~----~--v--------
1c:o1 (mm.Ho~ -"~~v.Jlll ... 1-w,· 
Attempted spontaneous 
respirat ions 
Allempted spontaneous 
respira tions 
Fig. 3-Intracranial pressure recording during posterior fossa sur-
gery demonstrating repeated elevation of ICP whenever the patient 
is allowed to breath spontaneously. This elevation of ICP is cor-
rected by assisting respiration (Top Tracing). 
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Fig. 4-Ceiling-mounted operating microscope in the 
neurosurgical operating room at the Medical College of Virginia . 
Focusing is accomplished by foot control pedal not shown in 
figure . 
brain without retracting the brain. Careful attention 
to the small metabolic parameters discussed above 
afford a much better opportunity to operate on the 
brain under relaxed conditions. Brain retractors 
should be used to protect the brain, not to retract the 
brain, and the tumor must be removed from the 
brain, not the brain from the tumor. The operating 
microscope has changed our approach not only to in-
tracranial vascular surgery, where it is absolutely 
necessary, but also to benign brain tumor surgery as 
well. Presently the only type of tumors not requiring 
use of a microscope are malignant gliomas of the 
cerebral hemispheres. 
At MCV a ceiling-mounted microscope allows 
the surgeon and one assistant or resident to see and 
become involved in the operation (Fig. 4). The best 
place to install a ceiling-mounted microscope is in the 
center of the operating room. Many surgeons prefer 
the floor-mounted movable microscope, finding it 
easier to move the microscope to the patient than to 
move the patient to the fixed microscope. The 
limitations of the microscope earlier in our ex-
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perience included the fact that it made resident 
teaching difficult and did not allow the scrub nurse or 
the anesthesiologist the opportunity to view the sur-
gery. A video tape camera can be attached to the 
operating microscope allowing both the scrub nurse 
and the anesthesiologist to view the surgery and also 
the televising of the surgery to any location in the 
hospital, providing greater flexibility of the mi-
croscope as a teaching instrument. 
The important lessons in developing excellent 
microsurgery techniques are learned in the 
microneurosurgical laboratory. An extended period 
of time must be spent in the laboratory learning how 
to handle and drape the microscope as well as to 
learn microneurosurgical instrumentation and 
techniques. The MCV division of Neurosurgery has 
such a laboratory, One should borrow neither the 
ophthalmologists' nor the otolaryngologists' mi-
croscope for an occasional neurosurgical operation 
nor purchase a set of a famous neurosurgeon's in-
struments and expect to immediately perform mag-
nification neurosurgery. 
With the proper use of the microscope, it is 
possible to approach any area in or near the brain to 
safely remove tumors while preserving vital structure. 
For instance, the microscope has been the primary 
reason for the renewed interest in the transsphenoidal 
approach to pituitary surgery. The small secreting 
tumors of the pituitary causing acromegaly can now 
be removed while preserving the pituitary gland (8). 
Summary. Reliable ICP measurement allows an 
exact quantitation and management of intracranial 
pressure. This precise assessment of ICP is a valuable 
adjunct in the management of anesthesia for brain 
tumor patients. The proper combination of ICP and 
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anesthesia management enables the surgeon to use 
the operating microscope to approach previously in-
accessible areas of the brain and to perform 
meticulous surgery with a better prognosis for the 
brain tumor patient. 
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Advances 1n the Management of Patients 
with Malignant Brain Tumors* 
CHARLES B. WILSON, M.D. 
Professor and Chairman, Department of Neurosurgery, 
University of California, San Francisco 
In describing what is new in the management of 
malignant brain tumors, I shall confine myself largely 
to chemotherapy and shall outline what we think is 
important based on our own experience, what we 
have achieved with single and multiple agents, and 
where we are going. We have just reviewed our five-
year experience and find that chemotherapy, perhaps, 
is the only thing that is new. 
The development of drugs since 1943 has been 
escalating at a fantastic rate. Today, we can provide 
the chemotherapist with a wide array of drugs from 
which to choose. 
Several neoplastic diseases are now recognized 
as being highly responsive to chemotherapy and the 
list is growing. The first to be recognized was 
childhood lymphocytic leukemia, then choriocar-
cinoma, and now testicular carcinoma and Wilm's 
tumor. 
The first consideration for effective brain tumor 
chemotherapy, as we see it, is that the agent must 
have optimum lipid solubility or a special transport 
system. We are convinced that it must penetrate the 
normal brain to be truly effective, and I shall indicate 
our reasoning below. 
One must achieve an adequate drug level in 
brain adjacent to the tumor with minimal or no 
neural toxicity, and the drug must be given frequently 
enough to produce maximal DNA damage with in-
sufficient time for repair. At the present time, we are 
studying the rate of DNA damage and repair in a 
search for combinations of drugs that will give less 
* This is an edited transcription of a lecture presented by Dr. 
Wilson at the 27th Annual Stoneburner Lecture Series, February 8, 
1974, at the Medical College of Virginia, Richmond. 
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than added toxicity and, at the same time, will 
produce synergistic antitumor effects. 
A water soluble compound is excluded by the in-
tact blood-brain barrier and, administered in-
travenously, the drug attains a high concentration 
only in the leaky, central portion of the tumor. As the 
drug moves toward ventricular and subarachnoid 
cerebral spinal fluid (CSF), the concentration falls 
very rapidly, so that the active periphery of the tumor 
is exposed to low concentrations of its drug and for a 
brief time orily. If one gives a water-soluble drug in 
the CSF, however, it moves quickly across the epen-
dyma into adjacent brain . It does not exit from the 
normal brain but diffuses through brain ipto tumor. 
This would be a reasonable way, then, to give a 
water-soluble drug. 
On the other hand, if one uses a lipid-soluble 
agent, for example, the nitrosoureas, it crosses 
capillaries in the normal brain. Obviously, it crosses 
the tumor's leaky capillaries, so that one has equal 
drug concentrations in brain adjacent to tumor and 
in tumor. If one injects a lipid-soluble drug into the 
ventricle, it crosses the ependyma, instantly goes out 
through the capillaries of the normal brain, and none 
of it ever reaches the tumor, unless it happens to be 
very close. It would be irrational to use a lipid-soluble 
drug intrathecally. With lipid-soluble compounds, 
concentration in the tumor is the same as concentra-
tion in the brain. We believe that this is important 
both froin the theoretical standpoint and from our 
own experience. 
Our group is interested in developing effective 
drugs and drug schedules in the laboratory and in 
bringing these into clinical trials. We started out with 
a rat glioma; now we have two rat gliomas and three 
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mouse gliomas, which we use for drug screening. In 
the past, we have used reservoirs in pups for in-
trathecal administration. We can perform intrathecal 
injections in the rat, so that it provides a model for 
therapy, either by continuous intra-arterial infusion 
or by intrathecal injection. We are not limited by the 
route of administration. It turns out that the models 
have been extremely useful, not. only for screening 
promising compounds but also for working out drug 
schedules and routes for administration. 
The kinetics of brain tumors are most important. 
We have studied animal tumors and have completed 
studies of human tumors in vivo. To summarize what 
we know about a glioblastoma at the present time, we 
have shown that in a glioblastoma, approximately 
30% of viable cells are actively dividing and the other 
70% of the cells are nondividing (nonproliferating). 
The cell cycle, that is, the length of time it takes a 
glioblastoma cell to go from one mitosis to two cells 
at the next mitosis, is somewhere in the range of 21/2-3 
days. Were it not for a very high rate of cell loss, the 
volume of a glioblastoma would double in ap-
proximately one week. This is unrealistic on the basis 
of clinical observation. We know that the period of 
time required for the glioblastoma cell to synthesize 
its DNA is about 9-10 hours and, interestingly 
enough, it takes an astrocytoma the same period of 
time. 
In our studies, we have used radioactive 
thymidine, labelled either with tritium or with 14C. 
We have documented the intense proliferation seen in 
blood vessels within a glioblastoma. In all probabili-
ty, the limiting factor in the growth rate of a 
glioblastoma is the rate at which the blood vessels can 
proliferate, because there is good reason to believe 
that the capillary endothelium cannot divide as rap- . 
idly as tumor cells. In brain adjacent tumor, in 
the absence of tumor cells, because of tumor 
angiogenesis factor, blood vessels proliferate in ad-
vance of invasive tumor. 
The brain presents a particular problem. After 
treatment with an effective chemotherapeutic agent, a 
dead cell takes up approximately twice as much room 
as living cell. The result is an increment of edema or 
swelling of tumor cells and an increase in volume. 
This increased volume can be detrimental because of 
the effects of an increase in intracranial pressure. 
Dead cells must be removed; although these cells are 
now nonviable, they are still present and therefore act 
as a mass. We have just completed studies on dead-
cell removal and have shown that when one puts 
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tagged, lethally irradiated cells in brain, muscle, and 
subcutaneously, brain has a most inefficient, sluggish 
means of dead-cell disposal. We are convinced, both 
from pathological studies as well as our own obser-
vations, that the brain is relatively inefficient in 
removing dead cells as opposed to other solid organs. 
At this period, we often have to use steroids to com-
bat increased intracranial pressure and the question 
arises as to what steroids do to tumors? 
Methyl prednisolone or any of the glucocor-
ticoids will increase the survival of tumor-bearing 
animals that receive the steroids. Thus, you can in-
crease the survival of a rat bearing a glioma by giv-
ing steroids. If one has a control group and a group 
treated with methyl prednisolone, and they are killed 
at the same time (in this instance on the 21st day) one 
finds that the tumors in the control animals vary 
pretty widely but •have a mean weight of 157 mg, 
whereas the tumors of the animals receiving steroids 
are much smaller with a mean weight of 36 mg. One 
can explain this difference in two ways-steroids kill 
tumor cells and steroids slow down the rate of cell 
proliferation. We now have evidence that the latter is 
true. There is no direct oncolytic effect on glial 
tumors, but the steroid simply puts certain 
proliferating cells into a nonproliferating state, and it 
also increases the period of time necessary for a cell 
to divide, that is, the cell cycle time. This became very 
important when we checked our own clinical 
statistics. Were we confusing ourselves in judging 
drugs by the concomitant use of steroids? To answer 
the question, we took consecutive patients. One 
group of patients never received steroids. With an ap-
proximately equal number of patients in both groups, 
we determined how many were chemotherapy 
responders, probable responders and nonresponders. 
The concomitant use of steroids did not change the 
frequency of response to chemotherapy. We have 
concluded that steroids have one major effect in the 
brain tumor patient, that of reducing cerebral edema. 
To date, we have no clinical evidence that they have 
any effect on tumor cells. 
The material that I intend to present is based on 
a particular group of patients. These are patients who 
either have tumors recurrent following surgery and 
radiation therapy or in whom the diagnosis of a 
malignant tumor could be made without any 
reasonable doubt and whom we elect to treat by 
chemotherapy rather than by radiation therapy. In 
the latter group, we do not insist upon a tissue 
diagnosis, feeling that the price of obtaining a tissue 
202 
diagnosis is to justify the biopsy of a glioblastoma or 
a brain stem glioma. For reasons that I shall point 
out, this is more often the case. 
Consequently, patients who are eligible for our 
Phase II trials are those either with recurrent tumors 
or with primary tumors who are considered can-
didates for primary chemotherapy without surgical 
verification. In addition, we treat a small number of 
patients with metastatic tumors. A phase II trial asks 
one question: Is the drug effective, that is, does this 
drug have some activity against the tumor? It asks 
neither what the cure rate is nor for how long. A 
phase II study is designed solely for searching out and 
identifying effective drugs. For a patient to be eligible 
for this kind of study, he must first be ineligible for 
other studies in our program. Second, with a 
pathological diagnosis or an unequivocal ra-
diographic and clinical picture, . the patient is de-
teriorating neurologically. Third, if radiotherapy 
has been given, it must have been completed at least 
three months prior to chemotherapy. Dead cells hang 
around after the completion of radiotherapy, and late 
improvement can occur following radiotherapy. As a 
matter of fact, since we have instituted this rule, we 
have actually confirmed delayed improvement up to 
three months after radiotherapy. Finally, the patient 
is expected to live at least two months, and we are 
sometimes wrong on that estimate, but the patient, or 
more often his family, understands the complications 
of chemotherapy. Parenthetically, I can say that we 
have lost approximately l % of our patients as a direct 
result of complications of chemotherapy; our mor-
bidity has been higher. Mortality has remained low 
because we have means of rescuing the patient who 
gets thrombocytopenia or leukopenia. 
Thirty-four patients were not treated because: l) 
we found no evidence of tumor regrowth, 2) we 
thought that they would live less than two months, 3) 
they declined treatment after understanding it, or 4) 
further surgery was elected. In the latter category, a 
benign fourth ventricle cyst was referred to us as a 
recurrent brain stem glioma, and we sent the patient 
back with diagnostic studies to the referring 
neurosurgeon who removed the cyst. Recently, I 
removed a nerve sheath tumor of the tenth nerve 
which had been misdiagnosed as a brain stem glioma 
and, after radiation therapy, was sent to us for 
chemotherapy. We have seen a ·variety of misdiag-
nosed lesions, emphasizing the need for careful study. 
In one patient, we thought radiotherapy was the 
treatment of choice. 
WILSON: MALIG.NANT BRAIN TUMORS 
To judge the effect of chemotherapy, we use two 
criteria. We have a third which will probably be 
added-the EEG (which came as a complete surprise 
to me). At first, I would not allow our elec-
troencephalographer to charge our patients, because I 
was convinced that EEG would be valueless, but it 
did just about as well as a scan in predicting whether 
a patient was better or worse. We, like others, will be 
looking to the EMI scanner for a fourth criterion. 
The two criteria on which our data are based are the 
clinical status and the brain scan. A patient classed as 
a responder is better clinically and his brain scan is 
better. A patient is designated a probable responder if 
clinical status is: l) improved and the brain scan is the 
same, 2) if the clinical status is the same and the brain 
scan is better, or 3) if both of them remain the same 
for at least three months in the case of me-
dulloblastomas and glioblastomas and six months 
for more benign tumors. A nonresponder de-
teriorates as judged by clinical status and brain scan. 
A certain number of patients in our series were 
nonevaluable. We determined, in retrospect, that 
patients surviving for less than two months after 
beginning treatment were not evaluable-again, 
because of the slow removal of dead cells. Ap-
proximately 15% of all responders were considered 
failures when they returned for their second course of 
therapy. If a patient receiving a course of 
chemotherapy is obviously worse six weeks later, it 
does not mean that the drug is ineffective, because 
among those patients who eventually turn out to be 
unequivocable responders, 15% have had an initial 
deterioration in brain scan and clinical condition. 
Several patients were nonevaluable because, in the 
beginning, we were inexperienced. In some, the 
neurological condition was not clearly deteriorating 
immediately prior to treatment; others failed to com-
plete one full course; and on five patients, we were 
unable to obtain an adequate follow-up. 
What can we expect in using single drugs? With 
BCNU (still the best single drug used to date), 27 of 
our 57 patients showed a response, a rate of 47% over 
a mean duration of nine months, and this a popula-
tion of recurrent tumors. CCNU has a response rate 
of 44% but for a shorter mean duration. Procar-
bazine, also a powerful drug with a 52% response 
rate, has a mean duration of six months. We are un-
able to give an explanation for the fact that when we 
combine BCNU and vincristine (which should be a 
good combination because vincristine is not toxic to 
the bone marrow), we get a response rate of only 45% 
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over four months. Although BCNU and CCNU are 
virtually identical and both are highly lipid soluble, 
BCNU seems to have a clear advantage. Procarbazine · 
is not lipid soluble, but it does proceed rapidly, in 
high concentration, into CXF. The three most effec-
tive single agents, thus, have in common bone 
marrow toxicity and very rapid entry into brain and 
into CSF. 
What of the patient who receives a first drug 
and, whether with or without response, then proceeds 
with a second drug? A response to a second drug is 
very small, probably for two reasons-one, a possible 
cross resistance and two, by the time of proceeding to 
a second drug, the patient is usually in poor 
condition. 
What can be said of tumor types as related to 
specific drugs? With malignant gliomas and 
astrocytomas or glioblastomas, the response is 
similar with all of the three most effective drugs. For 
ependymomas, BCNU is extremely good, one of our 
patients responding to BCNU as the second drug ad-
ministered. The other tumor-specific chemotherapy, 
which I shall go into later, is the combination of 
procarbazine, CCNU, and vincristine that seems to 
be highly effective for medulloblastomas. 
As must be well known, BCNU is given in-
travenously on various schedules; it is quite likely 
that we do not use the optimal schedule. One of our 
early patients, a quadriplegic with an ependymoma, 
had a fantastic response over several months to 
BCNU, but ultimately could not receive any more 
due to the development of cumulative bone marrow 
toxicity. One patient with a malignant astrocytoma, 
having been treated with BCNU for two years, shows 
no evidence of tumor regrowth after two and one-half 
years off treatment. One young boy, who had a 
recurrent ependymoma of the fourth ventricle with 
supratentorial metastases, tumor cells in his CSF, 
and recurrent tumor in his posterior fossa, was 
treated with BCNU for two and one-half years; he is 
attending college now with no evidence of recurrent 
disease after two years off treatment. 
The Brain Tumor Study Group has studied 
BCNU in a phase III trial, taking patients who had 
had a major craniotomy and removal of a supraten-
torial glioblastoma. Postoperatively, these patients 
were not dependent upon steroids and they ran-
domized within three weeks of operation; thus, this is 
a select group of patients treated in the early 
postoperative period. Patients who received no 
further treatment had a median survival of 15 
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weeks-a little less than four months, which seems to 
be a little on the low side. Those patients who re-
ceived only BCNU postoperatively had a median sur-
vival of 21 weeks; those who received irradiation 
therapy had a median survival of 30 weeks; and those 
receiving BCNU plus irradiation had a median sur-
vival of 40 weeks. How do we interpret this? Irradia-
tion and BCNU combined are better than either 
alone and better than no further treatment after sur-
gery as well. Of the various forms of adjuvant therapy 
reported for glioblastomas, the most effective is 
BCNU and irradiation combined following major 
tumor removal. At the time of this study, about four 
years ago, BCNU was used because it had been 
shown to be an active drug in phase II trials. 
One of the people in our laboratory became an 
expert at removing rat gliomas, and we evaluated ad-
juvant chemotherapy and surgery, using a rat brain 
tumor model. We asked: Are we giving BCNU at the 
right time? Should it be given before operation, with 
the operation, or afterwards? We tried various com-
binations of BCNU and surgery and in one group, we 
even added 5-FU to obtain early proliferating 
postoperative cells. The study showed that there was 
no combination of surgery and BCNU that was as 
beneficial as BCNU alone. I could not believe it and 
we repeated the experiments four times. The ex-
periments defied my prejudice and the basic laws of 
cell kinetics, and the results have now been submitted 
for publication. I do not believe, however, that on 
this basis, neurosurgeons will stop removing 
glioblastomas, but we did feel encouraged to treat a 
few human glioblastomas, diagnosed angiographi-
cally without histological verification. Of the pa-
tients treated in this way, only two harbored pri-
mary reticulum cell sarcomas that we called 
glioblastomas-not a large error. 
Procarbazine is a monoamine oxidase inhibitor 
and patients under treatment, therefore, cannot eat 
ripe cheese or take certain drugs. One patient, who 
showed excellent results by brain scan, became 
irreversibly psychotic, so it is not a perfect drug, but 
it does move rapidly into the CSF. In one of our first 
patients, with a recurrent medulloblastoma and a 
total spinal block, procarbazine alone melted away 
the mass. Though active against medulloblastomas, 
procarbazine alone is not as active as a more recent 
drug combination to be mentioned below. Its activity 
against malignant gliomas is similar to BCNU. 
Single drug therapy for solid tumors is rarely 
curative in animal ·or human systems after the tumor 
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reaches a clinical size. Those people interested in 
solid tumors, therefore, are looking to combination 
chemotherapy, using drugs that have qualitatively 
different toxicity and complimentary mechanisms of 
action to prevent the emergence of resistance clones, 
and are combining agents that act on cycling versus 
noncycling (nonproliferating) cells. 
Our first multiple drug protocol involved three 
drugs: CCNU, which we knew was active and could 
be given by mouth; vincristine, which was active and 
did not add toxicity to the bone marrow; and procar-
bazine, which we thought was an excellent drug. The 
course was given on a 28-day cycle: CCNU on day 1, 
procarbazine for the first 14 days, and vincristine 
twice (days 1 and 8). We obtained a response rate of 
57% (I cannot give the median duration, but it has 
produced some of the most dramatic responses we 
have seen with medulloblastomas.). We are now per-
suaded for the first time, that we have something safe 
enough and effective enough to justify designing a 
study of combining chemotherapy with radiotherapy 
for the immediate treatment of verified me-
dulloblastomas. Our response rate here has been 
well over 75%, but the patients do develop chronic 
bone marrow toxicity. For example, a little girl who 
came in with papilledema and huge subfrontal 
metastases had a normal brain scan two months ago, 
after receiving procarbazine, CCNU, and vincristine, 
but due to chronically depressed bone marrow, we 
are unable to give her more drug and she is expe-
riencing a recurrence. 
We tried the combination of Cytoxan® 
(cyclophosphamide), CCNU, and vincristine. We 
saw few responses and concluded that this is not an 
effective combination. 
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What are the approaches to more effective 
chemotherapy? We are convinced that drug com-
binations are the wave of the future. Simultaneously, 
we are trying to identify new effective single drugs 
and effective combinations of single drugs. We are 
now actually putting into practice schedules based on 
kinetic information, that is, cell cycle and number or 
percentage of proliferating cells. It may be possible to 
convert tumor cells that are nonproliferating into a 
proliferating state in which they are more susceptible 
to drugs specifically damaging to proliferating cells. 
Possibly, we can convert some normal cells, such 
as gut and bone marrow, from their normal 
proliferating state to a noncycling compartment, par-
ticularly bone marrow, so that it will not be 
devastated by the drugs we use. We do not have a 
single drug today that is specific for cancer cells and 
are always on a tight wire between poisoning the host 
and poisoning the cancer. 
We hear a great deal about enhancing immune 
mechanisms. In the one reported study, patients who 
were immunized did no better than those who were 
not. There are some very promising things on the 
horizon, but at the moment, I see no immediate role 
for immunotherapy. The successful acceleration of 
dead cell disposal, in which we are extremely in-
terested, will have some practical application. 
In summary, our studies have identified three 
agents individually active against a variety of brain 
tumors. Procarbazine belongs in another phar-
macological group, but BCNU and CCNU are 
similar. Combination chemotherapy holds great 
promise for brain tumor chemotherapy, and one of 
the two combinations evaluated by us is highly effec-
tive against medulloblastomas. 
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Pharmacokinetic Considerations. Pharma-
cokinetics is that area of pharmacology concerned 
with the absorption, distribution, metabolism, and 
elimination of drugs. The processes by which absorp-
tion, distribution, and elimination take place are 
referred to as unit processes. These occur in-
dependently and concurrently, and involve such ac-
tivities as absorption into the blood, elimination from 
the blood, distribution between the blood and tissue, 
inactivation in tissues, and finally, elimination from 
the blood. Drug handling by the body can be 
characterized by the rate for each step or, more often, 
the rate of all processes. Classification of observed 
kinetics for these rate processes includes first-order, 
zero-order, and capacity-limited kinetics. In the 
description of these processes, we will use total body 
elimination as the rnodel, as this is the way most data 
are handled clinically (1 ). 
The rate of first-order or exponential drug 
elimination is proportionate solely to the amount of 
drug present. The half-life is constant regardless of 
the quantity present. Thus, if the dosage is doubled, 
the half-life ~ill remain the same. 
* Presented by Dr. David at the 27th Annual Stoneburner 
Lecture Series, February 8, 1974, at the Medical College of 
Virginia, Richmond. 
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Zeto-order kinetics is the term used to describe 
processes where rates are constant per unit time; the 
time required to rid the body of one-half the drug is 
prolonged by increasing the body load. It is implied 
that the rate process is limited, and the rate of 
elimination is fixed. 
Capacity-limited kinetics describe a situation of 
a rate process being variable and between the limiting 
situations of first and zero-order. As the number of 
drug molecules approximates the number of 
metabolic sites, for example, special mathematical 
processes must be employed to describe the 
responses. As drug ievels rise: the rate approaches the 
zero-order rate (constant amount eliminated/ time) 
and as levels fall, first-order rates are approximated. 
If we consider the situation of drug overdose or 
intoxication, it may help to clarify these different 
kinetic patterns. If zero kinetics are operative as in 
alcohol, the patient will rid himself of the same 
number of milligrams each hour regardless of serum 
level. At high levels in the body, this constant amount 
is a very small percent of body load and the rate of 
decline of serum concentratiop is slow indeed. If first-
order kinetics attain, as with phenobarbital, the total 
body load in the intoxicated patient will decline to 
one-half in the same time as the amount in the patient 
with a therapeutic amount. The situation of sqtura-
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tion kinetics is an intermediate between the two. An 
understanding of these principles is important mainly 
for preventing intoxication, for efficient alteration of 
dosage, and for unqerstanding individual variations. 
While the determination of rate constants is im-
portant, other parameters are of concern. Absorption 
parameters include both the rate of absorption and 
the bioavailability or percentage of the drug absorbed 
which reaches the active sites in the body. Distribu-
tion parameters include not only the rate of distribu-
tion but also the volume of distribution or extent to 
which the drug is found outside the blood; this is 
affected by protein binding. Protein binding may be 
affected by disease states and other drugs. 
The pharrnacologic effect on the desired organ 
or organ system will be dependent upon the amount 
of time in the body, the time exposed to the target 
organ, and the specific properties of the drug used. 
The occurrence of side effects is dependent upon 
similar considerations. 
There are many patient variables such as in-
dividual physiology, pathology, and genetic 
characteristics, as well as developmental and en-
vironmental factors which effect drug response. A 
drug serum assay (drug level determination) is but a 
small part of the data necessary to make an intelligent 
judgment with regard to m~ximizing the desired 
effect in therapy. Serum assay determines only the 
quantity in the serum and basic assumptions must be 
made in regard to the organ or organ system where 
the drug is a'ctive. Many factors affect the 
relationship between serum concentration and drug 
effect. An understanding of pharmacokinetic prin-
ciples will result in less trial-and-error phar-
macotherapy and more frequent consideration of im-
portant variables. For example, if the physician, as 
his goal in treating the seizure patient, has established 
that a patient should have no subsequent seizures, 
then he will, with a basic understanding, be able to 
prevent some of the seizures which occur during the 
start-up and dosage-adjustment phases of drug 
therapy; he may also avoid intoxication. 
Clinical Considerations. The availability of drug 
assays and pharmacokinetic data has already pro-
vided some useful information for the clinician (2). 
This has increased our knowledge in four areas: 
the initiation of therapy, dosage regimens, routes 
of administration, and adjustment of dosage for 
the four basic anticonvulsants-phenobarbital, 
diphenylhydantoin (Dilantin®), primidone (Myso-
line®), and ethosuximide (Zarontin®). These are 
the most commonly used agents, and there are, 
consequently, more pharmacokinetic data regarding 
them. 
Initiation of Therapy. With respect to the ini-
tiation of dosage, there is a rule of thumb that can be 
helpful: If a maintenance dosage regimen is used to 
initiate therapy, four times the half-life of the agent 
will be required to achieve 90% of the ultimate serum 
plateau. Since such a long time is required to reach 
this plateau with some cjrugs, such as diphenylhydan-
toin, loading has been used, particularly to achieve 
rapid therapeutic levels . Phenobarbital a nd 
primidone, however, produce significant drowsiness, 
so they are usually not "loaded." With ethosuxi-
mide, employed in the treatment of absence seizures, 
loading doses are usually not used because of the 
mild nature of the seizure being treated. Agents with 
long half-lives, however, are, potentially, those with 
which the initial dose should be larger than the 
maintenance dose. 
The usual starting dose for phenobarbital is 5 
mg/ kg/ day in the child and about 1 mg/ kg/ day in 
the adult. The half-life is 18-70 hours in a child (3) 
and 55-120 hours in the adult (4). In general , the 
younger the individual, the shorter the half-life. 
The starting dose for diphenylhydantoin is 5-8 
mg/ kg/ day for the child and 4- 6 mg/ kg/ day for the 
adult. Once the therapeutic level is achieved, the ap-
parent half-life is 8-12 hours. Loading of 
diphenylhydantoin can be accomplished by giving 
three times the maintenance dose in three divided 
doses, three hours apart on the first day (5); the 
second day, the usual maintenance dose is given. 
Therapeutic levels are reached in 12 hours, and peak 
serum levels are usually achieved on the third day. 
Diphenylhydantoin may also be loaded intravenously 
with accompanying electrocardiographic monitoring, 
but not more than 50 mg/ minute should be given (6). 
The initial dose ofprimidone administered is less 
than the maintenance level because of the initial po-
tent hypnotic side effects. Usually, a maintenance 
dose of 20 mg/ kg/ day is sought. Switching a patient 
from phenobarbital to full maintenance primidone 
usually can be accomplished without producing 
sedative side effects. The half-life of primidone is 
short-3-12 hours (7). 
The starting dose of ethosuximide is 20 mg/ kg/ 
day. The half-life is a mean of 66 hours in an adult 
and 30 hours in a child. 
Dosage Regimens. Because phenobarbital and 
ethosuximide have long half-lives, once-daily ad-
DA YID, GARRETTSON: PRACTICAL ANTICONYULSANT PHARMACOKINETICS 207 
ministration can be employed, and because of 
diphenylhydantoin's slow absorption, it also can be 
given once daily. Primidone, having a relatively short 
half-life, generally, should be given three times a day, 
although some patients are well treated with twice-
daily dosage. Ethosuximide may have a gastric irri-
tant effect, so some clinicians employ it in a twice-
daily regimen. 
Routes of Administration. Ethosuximide and 
primidone can be given only orally. Phenobarbital 
can be given orally, intramuscularly or intravenously. 
While diphenylhydantoin can be given orally or in-
travenously, intramuscular administration usually 
fails to release sufficient diphenylhydantoin to the 
blood, when given as the usual maintenance dose. 
Doubling the maintenance dose when giving it in-
tramuscularly is satisfactory, particularly when using 
this route for short-term replacement of oral therapy, 
as in surgery (8). 
Adjustment of Dose. In adjusting the level of 
medication, one should remember that phenobarbital 
and ethosuximide are eliminated by first-order 
kinetics and diphenylhydantoin, by capacity-limited 
kinetics (9). Consequently, doubling the dose of 
phenobarbital will double the blood level, as trebling 
the dose will triple the blood level. When levels of 
diphenylhydantoin are low, a similar relationship ex-
ists. At higher levels, in practice, apparently, above 10 
µg / ml, the effect of capacity-limited kinetics is that 
apparently relatively small dosage increments result in 
greater serum level increases than is expected or 
desired. Half increments are probably in order here. 
The therapeutic ranges given for phenobarbital levels 
are 10- 50 µg / ml, for prlmidone are 5-20 µg/ ml, and 
for ethosuximide are 40-80 µg/ml. The therapeutic 
range for diphenylhydantoin is 6-20 µg/ ml. Recent 
work indicates that low serum levels are effective in 
controlling seizures particularly in children. 
Compliance. While our knowledge of phar-
macokinetics has increased, one larger problem exists 
in the area of compliance. Compliance is poor when 
administration of the drug is too frequent, when mul-
tiple drugs are used on a different schedule, and when 
the dosage form is unacceptable. 
Three of the anticonvulsants mentioned can be 
given as infrequently as once a day. This eliminates 
the necessity for children to take these agents in 
school. When multiple agents are given, it is relatively 
easy to give all medications at one time. 
Phenobarbital is available as an elixir, diphenyl-
hydantoin and primidone, as suspensions. Where .it is 
possible, the tablet form assures a more reliable 
dosage intake. In the young child, all can be crushed 
and given with jelly or other vehicles. Di-
phenylhydantoin comes as a chewable tablet, and 
while it may produce more gingival hypertrophy than 
the capsule, we continue to use it extensively. 
Ethosuximide constitutes a rather special problem 
being a liquid within a rather large gelatin capsule. 
The capsule can be pricked by a pin and the liquid 
mixed with juice or another vehicle by the pharmacist 
or mother. One ingenious mother related that the 
capsule can be frozen, then cut in half and given with 
ice cream. 
Memory crutches are useful. The most inexpen-
sive is the traditional egg carton. Dial-a-packs are 
also available and can be loaded by the patient with 
his drug or drugs. 
A new era is here. Practical pharmacokinetics, 
skillfully utilized by the clinician, should aid im-
measurably in producing seizure-free patients and in 
reaching the goal quickly with fewer side effects. 
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Management of Intractable Partial 
Complex Seizures* ** 
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Introduction. Seizures can be due to a variety of 
acute, subacute, or chronic diseases with different 
etiologies. Clinically, they may manifest as focal or 
generalized phenomena (Table 1). Whereas the ma-
jority of the patients suffering from partial seizures 
are easily controlled with medications, in a small 
number of patients treatment may fail. The failure 
may be due to incorrect diagnosis or incorrect 
therapy. The efficacy of medical treatment for seizure 
disorder depends upon six factors: 1) dosage; 2) the 
size of the patient; 3) drug interaction; 4) drug 
specificity for the disease; 5) the nature of the disease 
for which the drug is used; 6) the mode and frequency 
of medication. 
Dosage of Anticonvulsant. The dosage of anti-
convulsant is very important (Table 2). ln our ex-
perience, the most common cause of failure in treat-
ment of seizure disorders is undermedication. It is 
also well known that the anticonvulsants in large 
enough doses can act as convulsants. This is espe-
cially true for diphenylhydantoin, benzodiazepines, 
and lidocaine. An important factor in dosage of drug 
is patient reliability. Measurement of blood levels of 
anticonvulsant can be helpful in this respect (Table 3). 
Size of the Patient. The size of the patient 
should be considered in dosage. Measurement accord-
* Presented by Dr. Hooshmand at the 27th Annual 
Stoneburner Lecture Series, February 7, 1974, at the Medical 
College of Virginia, Richmond. 
** This study was supported by a grant from Hoffman La-
Roche Co. 
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ing to body surface is safer and more accurate 
(Table 2). As the child grows, there may be a need to 
gradually increase the dose of anticonvulsants if 
seizure control is pqor or if the serum level of the an-
ticonvulsant starts to decline. 
Drug Interaction. The relationship of multiple 
drug therapy to its toxic effects on the brain is quite 
complicated, and many forms of therapeutic failure 
or toxicity can result. 
Combination of Similar Drugs. Failure or toxicity 
may be the result of a combination of phar-
macologically similar drugs. Such a combination may 
enhance the side effects of drowsiness and ataxia. The 
patient may suffer from these side effects without at-
taining therapeutic levels of individual anticon-
vulsants in the blood. For example, a combination of 
drugs such as phenobarbital and primidone may 
result in severe ataxia and drowsiness while measure-
ment of serum levels of phenobarbital and primidone 
in such patients may show subtherapeutic levels. 
The combination of the following phar-
macologically similar drugs should be avoided: 1) 
phenobarbital and primidone, mephobarbital 
(Mebaral®), and metharbital (Gemonil®); 2) etho-
suximide and methsuximide; 3) diphenylhydantoin 
(DPl-1) and mephenytoin; 4) trimethadione and 
paramethadione; 5) benzodiazepines (e.g., combina-
tion of diazepam, clonazepam (Clonapin®), chlor-
diazepoxide); 6) phenobarbital and ethanol; 7) 
phenobarbital and benzodiazepines. 
Combination of Inducers of Drug Metabolism. 
This combination may result in less effective 
MCV QUARTERLY 10(4): 208-219, 1974 
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TABLE I 
A Simple Classification of Seizure Disorders• 
I. Focal {partial) 
a. cortical 
b. subcortical 
c. both cortical and subcortical 
2. Generalized 
a. low threshold (e.g. drug withdrawal, toxic-metabolic, 
benign febrile seizures) 
b. secondary to focal 
* Any of the above may be clinical or subclinical (EEG 
manifestation). 
therapeutic doses of each drug in the blood, and less 
effective control of seizures, despite toxic side effects. 
Whereas the failure may be due to genetic, phar-
macological or physiological factors which alter ab-
sorption metabolism or excretion of the drug, or the 
failure may be due to compliance behavior of the 
patient or to lack of drug specificity for the disease, 
the clinician may add other anticonvulsants which 
are inducers of drug metabolism and may result in 
toxicity without control of seizures. The combination 
may fail to control the seizures, but may result in side 
effects of drowsiness (1) and/ or hyperactivity, also. 
For example, diphenylhydantoin (DPH) at 5 
mg/ kg/ day would result in a stable blood level of the 
drug (2); however, an occasional patient on the same 
dosage may represent marked blood accumulation of 
the drug and toxicity (3), while others on the same 
dosage may reveal very low drug levels and poor 
TABLE 2 
Dosage, Therapeutic Drug Levels, Indications, and Side Effects of Routinely Used Anticonvulsants 
TD 50 Safety Serum Level• 
Average Daily Dose {Toxicity) Range Therapeutic Skin Rash Hyper-
Indications (ED 50) (mg/ kg) (TD/ ED) Range Leukopenia activity 
DPH 
(Dilan tin®) F, G, S 5 mg/ kg (0.3 g/ sqM) 20 4 I0-20 µg/ ml ± ± 
Phenobarbital 
(Luminal®) F, G, P, C, S I .5 mg/ kg (0.1 g/ sqM) 4.5 3 I0-50 µg/ ml ± +++ 
Primidone 
(Mysoline®) L, G 10 mg/ kg (0.6 g/ sqM) 140 I4 4-I2 µg/ ml ± + 
Ethosuximide 
(Zarontin®) p 20 mg/ kg (1.2 g/ sqM) I50 IO 40-IOO µg/ mI + + 
Methsuximide 
(Ceiontin®) P, C 10 mg/ kg (0.6 g/ sqM) 15 1.5 2-7.5 µg/ mI ++ + 
Trimethadione 
(Tridione®) p 20 mg/ kg (1.2 g/ sqM) 25 1.2 IOO-IOOO µg / mI +++ + 
Diazepam 
(Valium®) S, P 2-IO mg IV repeated 30 IO I50-550 ng/ mI ++ 
dose 
Clonazepam* S, P, C 0.3 mg/ kg 6 20 20-70 ng/ mI +++ 
Acetazolamide 
(Diam ox®) P, PMS 500-750 mg/ day 200 I8 I0-75 µg/ ml 
Carbamazepine* 400 mg (children)/ day 
(Tegretol®) L, G 1200 mg (adults)/ day 23 1.5 4-6 µg/ ml ± + 
ACTH Infantile spasms 40-80 u 
ED-Effective dose g/ sqM-gram per square body meter 
C-Complex (myoclonic akinetic, focal and gen., "petit mal variant") TD-toxic dose 
F-Focal seizure ±-Rare 
G-Generalized + -Infrequent 
L-Limbic (Temporal lobe, etc.) ++-Occasional 
P-Petit mal +++-Not uncommon 
PMS-Premenstrual seizures * -Use as anticonvulsant experimental 
$-Status epilepticus :j:-Gross guidelines 
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TABLE 3 
Measurement of Blood Levels of Anticonvulsants 
I. Patient reliability 
2. Undermedication and overmedication 
(typical and atypical toxicity; acute and chronic toxicity) 
3. Drug interaction 
4. Seizure aggravation by anticonvulsants 
5. Neurologic deterioration due to drugs vs other causes 
6. Use of anticonvulsants in hepatic or nephritic patients 
seizure control (4). Notwithstanding this variability 
in individual patients, the clinician may become 
frustrated with the patient's Jack of response to treat-
ment. Without further inquiry as to the cause of this 
Jack of response, the clinician may add sub-
therapeutic doses of other drug inducers. The com-
bination is apt to fail. 
The combination of the following inducers of 
drug metabolism should be avoided: 1) phenobarbital 
and antipyrine; 2) phenobarbital and butazones; 3) 
. phenobarbital and diphenylhydantoin (DPH); 4) 
phenobarbital and gyrseofulvin; 5) chlordiazepoxide 
and Coumadin®. 
Drug interaction is variable from case to case; 
however, high anticonvulsant levels are achieved of 
each drug, if the metabolic inducers are not given 
simultaneously (5). If in some cases a combination of 
drugs seems to be more effective, it is most likely that 
subtherapeutic doses of each agent have been used to 
begin with. This is especially true in combining 
phenobarbital and DPH. 
The combination of phenobarbital and DPH is 
in vogue. While in occasional patients such a com-
bination may be more rewarding than the individual 
use of phenobarbital or DPH, _in our study of 182 
patients suffering from focal as well as gen-
eralized seizures (Table 4), patients responded bet-
ter to phenobarbital or DPH alone than to the 
combination of the two drugs. When the patients 
were randomly divided into three groups, the group 
receiving DPH and phenobarbital in combination 
had more tendency to suffer from side effects of 
drowsiness and ataxia, and therapeutic levels of the 
anticonvulsants could not be achieved in most cases 
without the complications of undesired side effects. 
The patients who received single anticonvulsants had 
a higher level of serum anticonvulsants with fewer 
side effects of drowsiness, poor appetite, and 
hyperactivity. The patients in the combination group 
had more rapid control of seizure disorder from the 
start, but did not fare as well in the long-term follow-
up. This was blamed on the fact that the patients on 
combination therapy did not follow the treatment 
schedule as religiously as the patients in other groups 
because of the side effects. The patients receiving in-
dividual anticonvulsants had a delay of two-to-five 
days in complete control of their seizures, but had 
better control of seizure disorder when followed for a 
period of over two years (Table 4). 
Drug toxicity can be enhanced by the use of hor-
mones such as salt-retaining hormones or by the use 
of psychotherapeutic drugs such as phenothiazines. It 
is a well-known fact that phenothiazines can exacer-
bate seizures in some patients; this is especially true in 
patients suffering from limbic system originated 
seizures. This does not, however, contraindicate the 
use of phenothiazines in the epileptic patients. The 
use of some phenothiazine drugs may be absolutely 
necessary to control the emotional problems which 
TABLE 4 
DPH 
5.0 mg/ kg/ day 
Phenobarbital 
1.5 mg/ kg/ day 
Combination 
Treatment of Focal and Generalized Seizures in 182 Randomly Distributed Patients 
Age Range 6-37 Years with a Two-Year Follow-up 
No. of Mean Blood Mean Blood 
Patients DPH (µg/ ml) Phenobarbital (µg/ ml) 
61 II 
51 12.3 
62 6.2 7.1 
Therapeutic Failures 
in Two Years 
13 (21.3%) 
16 (27.1 %) 
24 (38.6%) 
(Reproduced by permission of the American Academy of Pediatrics, Inc., and the author, from H. Hooshmand, "Toxic Effects of An-
ticonvulsants: General Principles," Pediatrics 53:553, 1974.) 
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Fig. IA-Frequent, partial , complex seizures in a three-year-old 
boy diagnosed as "petit mal" without success. 
may be more incapacitating than the seizures 
themselves. Among the phenothiazines, however, the 
epileptogenic effect is variable. For example, chlor-
promazine (Thorazine®) is a much stronger epilep-
togenic agent than thioridazine (Mellaril®); the use of 
the latter drug is more strongly preferred of the two. 
Drug Specificity for the Disease. Whereas in 
therapeutic doses, anticonvulsants have in common 
the characteristic of raising the threshqld of the 
seizure discharge, clinical experience has revealed 
that some of the anticonvulsants are more useful for 
specific forms of seizures. The review study by 
Coatsworth (6) has demonstrated that ethosuximide 
is more effective in the treatment of petit mal. 
Trimethadione is less effective in petit mal and is not 
effective in treatment of generalized convulsive 
seizures. Primidone is more helpful in the treatment 
of limbic (psychomotor) seizures and is not effective 
in petit mal seizures. If these guidelines are used, the 
medical treatment will be more successful (Table 2). 
22,17~N 11-30-17 
3 ''· old N. M. 3 W.elll Loter. 
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Fig. IB-Methsuximide, 300 mg per day, stopped the seizures. 
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Fig. 2-Temporal lobe seizures in a 12-year-old boy misdiagnosed 
as "petit mal." 
It should be kept in mind that an anticonvulsant 
may be very effective experimentally for a specific 
form of seizure, but it may have a narrow safety 
range measured by toxic dose compared to effective 
dose (7) (Table 2). The toxic side effects will limit the 
usefulness of such an anticonvulsant. This is true for 
trimethadione and phenacemide. Phenacemide, an 
anticonvulsant tried for treatment of temporal Jobe 
seizures, is so toxic that its use is unwarranted (6). 
The Nature of the Disease for Which the Drug 
is Used. Therapeutic failure may be the result of in-
correct diagnosis such as the treatment of hysterical 
seizures with anticonvulsants. Other examples may 
include treatment of psychosensory seizures 
originating from the temporal lobe, misdiagnosed as 
petit mal, with medications for petit mal seizure or 
treatment of complex infantile seizures as "petit ma!" 
seizures (Figs. 1, 2). 
Electroencephalography (EEG) can be a 
priceless tool in confirming the diagnosis. One cannot 
always rely on clinical expertise and judgment in 
diagnosis of seizure disorder; EEG must be used as a 
guideline for accurate diagnosis and treatment. 
Accurate diagnosis of etiologic factors in seizure 
disorder is most important in the treatment of 
neonatal seizures. More than half of these neonatal 
seizures may be caused by correctable factors such as 
calcium, magnesium, glucose, or pyridoxine 
metabolism disturbance (8). If instead of correcting 
these metabolic disturbances, anticonvulsants in 
large doses are used, the infant can easily be born 
toxic. 
The problem of the "breakthrough effect" can 
play a significant role in drug toxicity. This problem 
refers to the phenomenon of the loss of control of 
seizures despite adequate therapeutic blood levels of 
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anticonvulsants after a few months or years of 
successful !reatment. Some anticonvulsants are more 
apt to develop this problem. These include 
acetazolamide (Diamox®), nitrazepam (Mogadon®), 
and, to a lesser extent, diazepam (Valium®) and 
clonazepam (Clonopin®). 
In our experience, the breakthrough effect may 
also be related to the etiologic factors. In rare cases of 
slow-growing gliomas with temporal or frontal lobe 
seizures, the breakthrough effect may herald the 
presence of the tumor years before the tumor can be 
visualized by contrast studies. 
The Mode and Frequency of Medication. The 
route and the frequency of administration of anticon-
vulsants plays a role in efficacy and toxicity. The 
frequency of administration should be approximately 
equal to the half-life of the drug (which is quite 
different from one drug to another). 
Diphenylhydantoin ( DPH ). The approximate 
half-life of DPH in man ranges from 4-50 hours ac-
cording to various studies. The mean figure is 22 
hours. Unfortunately, all patients do not fall in the 
mean rate of plasma half-life. As a result, single-dose 
administration of DPH can cause fluctuations of the 
drug level in the blood in a small number of patients 
causing confusion in treatment. This method, which 
apparently can be quite effective in adults (9), can 
cause some complication in children. In our ex-
perience, a single-dose administration of DPH can be 
irritative to the stomach, causing nausea and 
vomiting. There is no need, however, of dividing the 
dosage of DPH to more than two times per day. This 
drug should never be given intramuscularly (IM), but 
can be administered intravenously or by mouth; IM 
use ·causes necrosis of muscle and DPH is not 
transferred to the blood from the muscle in any 
significant therapeutic dose. DPH should not be mixed 
with other IV fluids because it is strongly alkaline. 
Long-term administration of over 7 mg/ kg of 
DPH causes lethargy, drowsiness, diplopia, confu-
sion, and ataxia; ataxia and nystagmus are crude 
signs of toxicity. Rarely, hyperactivity, poor school 
performance, psychosis, hallucinations, and de-
lusions may result. Hirsutism, seen in three-fourths 
of all patients taking DPH, is annoying but not 
serious. Gum hypertrophy is also frequently seen and 
can become so severe as to necessitate excision. 
Morbilliform rash may occur in 2% of patients; 
in these cases, DPH will have to be discontinued. 
Even though some patients can later be restarted on 
the drug, this is a risky practice. The rare com-
plications of blood dyscrasia and hepatitis definitely 
necessitate the permanent discontinuation of all 
hydantoins. 
A common benign side effect of DPH is 
lymphadenopathy. We have seen this to be mis-
diagnosed as lymphoma or lymphosarcoma. Lupus 
erythematosus (LE) is a rare complication which 
clears up after the discontinuation of DPH. The fami-
ly history is positive for LE in one-fifth of these 
patients. Another rare complication of DPH therapy 
is a mild megaloblastic anemia which can be cor-
rected with 0.1 mg folic acid daily. 
Phenobarbital. This anticonvulsant has a half-life 
of three-to-six days in man. As a result, a single daily 
dose should be efficient and effective. This single dose 
is best given at bedtime. 
The main side effect of this drug is drowsiness 
and/or aggravation of preexisting hyperactivity. 
This side effect can be effectively overcome by the ad-
dition of methylphenidate (Ritalin®), 10-30 mg in 
divided doses in the morning and at noon. A 
scarlatiniform rash may develop in 2% of patients. 
This necessitates discontinuation of the drug as does 
allergic erythematosus rash. 
Primidone ( Mysoline®). This drug has a plasma 
half-life of 4-19 hours in man with a mean of eight 
hours . It should not be given as a single dose, and 
preferably should be given every four-to-eight hours; 
tolerance to this drug develops slowly. 
Diazepam (Valium®). This drug is effective 
mainly as an anticonvulsant for the control of status 
epilepticus. It should be given in IV form in frequent 
doses. The half-life of this drug is not more than three 
Fig. 3-Manning (16) depth electrode. (Right) The depth electrode 
with six exposure points 5-10 mm apart. (Left) The electrodes seen 
in the middle fossa and anterior fossa of the skull. Arrows show 
points of exposure. 
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TABLE 5 
Cases of Intractable Seizures Excluded After Adjustment 
of Standard Rx• 
hours. As a result, frequent injections should be given 
until the seizure is under control. Diazepam should 
not be given IM or by mouth for the treatment of 
status epilepticus; neither should it be mixed with 
other IV medications; it is most incompatible with 
most other IV fluids . This incompatibility manifosts 
itself in the form of venous blood coagulation and 
pulmonary em bolus, which may have been the major 
factor in blaming this drug for the rare complications 
of respiratory arrest and death that are due to ben-
zodiazepines. 
U ndermedication 
Drug interaction 
Drug toxicity 
Wrong diagnosis and Rx: 
petit mal vs limbic seizures** 
petit mal vs complex seizures*** 
hyperventilation syndrome 
conversion reaction 
1 hypoglycemia, 1 lead poisoning 
and 1 congenital heart disease 
Total 
6 
4 
4 
5 
1 
2 
3 
26 
* Of the 70 patients referred for intractable seizure, 26 
were satisfactorily treated after correction of diagnosis or 
adjustment of medication . 
Clonazepam. This is an effective anticonvulsant 
in the treatment of petit mal as well as complex minor 
motor seizures ( 10, 11 ). Its half-life is five-to-six hours 
and it should be given by mouth every six hours . The 
major side effects are drowsiness (when given in toxic 
doses) and aggravation of hyperactivity. The 
hyperactivity can be corrected by treatment with 
methylphenidate (Ritalin®). 
** One case treated successfully with primidone alone, 
three cases with carbamazepine. 
*** All five responded favorably to methsuximide. 
Trimethadione. Because of the high tendency for 
toxicity in the form of skin rash, blood dyscrasias, as 
well as hemeralopia, and because the diones are not 
as effective anticonvulsants as succinimides (6), we 
TABLE 6 
Results of Treatment with Clonazepani in 44 Cases of Uncontrollable Seizures 
Type of Seizures 
Petit inal (absence) 
Photic sensitive 
Petit mal status (absence-
continuing) 
Sylvian 
Myoclonic 
Temporal lobe (psycho-
motor, psychosensory) 
Focal cortical 
A kinetic 
Complex (akinetic and 
myoclonic) 
I nfatitile spasm 
S & W-spike and waves 
Number of Cases 
5 
1 
5 
7 
4 
10 
7 
2 
EEG 
Gen. S & W 
Photoconvulsive 
Cont. S & W 
Mid-temporal S 
S & W plus frontal or 
temporal S 
Temporal S 
Follow-up EEG* 
Infrequent or no S & W ; 
focal S 2 cases; slow back-
ground 3 cases 
Normal 
Slow background 
No S & W 
Less frequent S 
l'{ o change 
Slightly less frequent S 
Focal S (motor 3, Occip. I) No change 
S & W, poly S 8:j: plus 
frontal 3 temporal S 2 
hemispheric 1 
Focal or gen . multiple 
· spikes 
Hypsarrhythmia 
± 
± 
No change 
* Low voltage fast activity was invariably present 
** 4+ excellent control , - 3+ over 75%, 2+ over 50%, + over 25% decrease of seizures, - no change 
*** ± temporary effect 
:j: Simultaneous EEG anomalies were common 
t Expired (meningitis) 
Results of Rx** 
++++ 3 cases 
± 2 cases 
++++ 
++++ 
++++ 
+++ 3 cases 
± 2 cases 
++++ 4 cases 
± *** 3 cases 
++ 3 cases 
± 1 caset 
+++ 6 cases 
++ 2 cases 
± 2 cases 
± 6 cases 
++ 1 case 
- 2 cases 
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TABLE 7 
Results of Surgical (Ablation) Therapy iii Eight Intractable Seizure Patients 
with a Two-to-Eight Year Follow-up 
X-Ray Age at Ohset Age at Seizure Control* 
Seizure Fingings of Seizures Surgery Procedure Pathology After 2-7 Years 
Psychomotor Neg 8 yrs 14 yrs temporal glioma III ++ ** 
lobectomy 
Psychomotot Neg 9 yrs 15 yrs temporal oligodendro- +++ 
lobectomy glioma 
A kinetic Neg 11 yrs 17 yrs temporal no lesion + ++ 
lobectomy 
Akinetic Neg 9 yrs 21 yrs temporal gliosis + ++ + 
lobectomy 
Akihetic & Neg 2 yrs 6 yts frontal lobe AV malformation ++++ 
advetsive section 
Akinetic & Neg 12 yrs 22 yrs frontal lobe gliotic cyst ++++ 
grand ma! section 
Complex (akinetic, Hemiatrophy Birth 11 yrs Hemi- atrophy ++++ 
focal , gen.) spherectomy 
Grand mal R. occip. I yr 19 yrs Removal of gliosis ±t 
cyst cyst 
* 4+ excellent control, - 3+ over 75%, 2+ over 50%, +over 25% decrease of seizures, - No change 
** 4 yeats postop, post Ro-Rx, and post chemo-Rx 
t Died of E. coli meningitis 13 months postop 
have abandoned the use of this drug altogether. The 
usual dose in children with petit rnal is 300-900 mg/ -
day in two-to-three doses. 
Succinimides. At present, ethosuximide (Zaron-
tin®) is the drug of choice for petit mal seizures (6). It 
can aggravate generalized convulsive episodes in 
akinetic and temporal lobe seizure patients {12). 
Because of its long half"life, once- or twice-daily 
doses should be sufficient. It is metabolized as quickly 
in children as in adults. 
Methsuximide (Celontin®). In our experience, 
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Fig. 4-EEG of 14-yeat-old boy suffering from psychosensory 
seizures with cortcomitant fluttering of eyes. Note 3/ sec S&W 
followed by a left temporal spike transient. Poor response to 
ethosuximide treatment. · 
this has been a very useful drug in the treatment of 
difficult to control (akinetic, myoclonic, etc.) seizures. 
One daily dose seems to be sufficient. It has more 
tendency for toxic side effects than does ethosuximide 
{Table 2). Phenylsuccimide, a bi product of this drug, 
has a long half-life and can cause deep coma ( 13). 
Carbamazepine ( Tegretol® ). Because of fluctua-
tion in blood levels, this drug should be administered 
three-to-four times daily. Blood levels of over 7 
µg / ml may result in ataxia, nausea, diplopia, 
dysarthria, and drowsiness, all dose-related {Table 2). 
TABLE 8 
Outcome of 70 Cases of Difficult Seizure Control with 
Two-to-Eight-Year Follow-up 
Management Patients Successful Rx 
Drug adjustment, 
misdiagnosis 26 23 
Clonazepam 44* 27 
Surgery [8]* 6 
Total 70 56 
Failures-14 cases 
(20%)** 
• The surgical cases were from the clon~zepam failure group. 
•• The failure rate was descreased from 100% to 20%. 
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TABLE 9 
Results of Medical and Surgical Treatment in 32 Patients 
Suffering from Akinetic Seizures* 
Lennox syndrome 
(age at onset birth-
5 yrs, average IQ 78) 
Complex Akinetic 
(age of onset 1-12 
yrs, average IQ 82) 
and Myoclonic 
Late Onset Akinetic 
(age of onset 5-13 
Patients 
7 
18 
yrs, average IQ 89) 7 
Total 32 
Intractable 
5 
6 
11 
* Note the relationship of patients' age to the prognostic 
response to therapy-the later the age of onset of the 
disease, the beiter the prognosis. 
Rare serious, al\ergic-type complications of blood 
dyscrasia, hepatitis, and skin rash may necessitate 
discontinuation of this drug (14); however, this drug 
can be quite safe and effective in the treatment of 
seizure disorders in children ( 15). 
Adrenocorticotrophin (ACTH). This is the drug 
of choice in infantile spasm. Although it can cause 
cushingoid features, this side effect is worth coping 
with. Every-other-day dose decreases this side effect. 
Management of Intractable Seizures. The follow-
ing is our experience with the management of intrac-
table seizures. 
Material and Method. Seventy intractable partial 
seizures were studied and followed for two-to-eight 
years. Patients who demonstrated the evidence of 
brain tumor or arteriovenous (AV) malformation on 
contrast studies were excluded from this study. The 
70 patients were evaluated for medical or surgical 
treatment. Age range was 2-34 years with an average 
of 14 years. The majority of patients were in 
childhood and teen-age groups. Thirty-eight were 
female, 32 were male. 
The depth electrode studies were done on the 
patients who had failed to respond to medical treat-
ment, and regardless of the type of generalized EEG 
discharges, showed focal spikes in their ictal, interic-
tal, or postictal EEG recordings. Manning (16) depth 
electrode was used. This is a fine depth electrode, 
thinner than other types, which can be inserted with 
little risk of trauma (Fig. 3); its six exposure points, 
5-10 mm apart, facilitate recording several points in 
depth. 
The depth studies were performed immediately 
after contrast studies, psychological tests, as well as 
an intra-arterial amobarbital test for diagnosis of 
cerebral dominance. The ventricular air remaining 
from the .air encephalogram was an important guide 
in locating the position of the depth electrodes. The 
depth electrode studies consisted of the study of the 
suspicious focal discharge as well as symmetrical 
depth electrodes positioned in temporal lobes, frontal 
lobes, and thalamic nuclei . The temporal lobe elec-
trodes were inserted from the posterior temporal 
region, advancing towards the amygdaloid nucleus 
with the tip of the electrodes resting adjacent to this 
nucleus (Fig. 3). This method would provide a record-
ing from surface to depth, from posterior to anterior 
aspects of the temporal lobes, and would facilitate 
localization of the abnormal discharges. An average 
of ten days-to-two weeks of recordings were done and 
an attempt was made to record an ictus on depth elec-
trode recording of all patients with the help of all-
night EEG n;:cordings or EEG telemetry recordings. 
Results. Twenty of the patients were helped by 
adjustment of standard medical treatment (Table 5). 
Six patients were found to have been misdiagnosed. 
This group consisted of one patient with lead poison-
ing, one with hypoglycemia, and one patient with 
congenital heart disease. 
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Fig. 5-Six-year-old girl suffering from intractable seizures. Sur-
face EEG recording shows slow S&W. EEG returned to normal 
after removal of a right mesial frontal A Y formation. 
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The remaining 44 patients were tried on a ben-
zodiazepine-clonazepam (Table 6). This drug was 
most effective in petit ma!, petit ma! status, and 
photosensitive seizures. It was less effective in com-
plex seizures and infantile spasm (hypsarrhythmia). 
Of the 27 patients who failed to respond to 
clonazepam therapy, 15 underwent depth electrode 
studies. Of these 15 patients, eight eventually had sur-
gical treatment. These eight patients were selected 
after the depth electrode studies revealed that the 
epi!eptogenic focus was the source of the patients' 
clinical seizures and was amenable to surgical treat-
ment (Table 7). 
Despite the fact that repeated angiography and 
air encephalography performed in intervals as far 
apart as three-to-six years were negative before 
operation, with the help of depth electrodes, lesions 
such as tumors and AV malformation were found at 
the site of epileptogenic focus (Table 7). The end 
result was a drop of failure rate from 100% before the 
study to 20% at the completion of this study 
(Table 8). 
Discussion. The clinical and surface EEG 
diagnoses are not always accurate. The interictal sur-
face EEG findings do not necessarily correlate with 
the region of the epileptogenic focus, and may not be 
localizing in even half of the partial, adversive, or 
controversive seizures (17, 18). Simultaneous depth 
and surface recordings in patients with petit mal 
epilepsy reveal inconclusive data regarding the site of 
origin of both the spike and slow wave discharges 
(19-21). 
Experimentally in the monkey, the electrical and 
behavioral characteristics of petit mal epilepsy have 
been demonstrated by the production of bilateral cor-
tical eplieptogenic foci (22). It has been shown that 
the focal cortical paroxysmal discharge has a tend-
ency for subcortical propagation before maturation 
and a tendency for cortical propagation after matura-
tion (23). A synchronized EEG discharge is not 
necessarily synonymous with subcortical origin. A 
cortical focus can give rise to similar seizure 
manifestations (29). In occasional cases, the suppres-
sion of the generalized 3/ sec spike and wave (S & W) 
discharges by medication may help demonstrate the 
cortical epileptogenic focus ( 10). The diagnosis of 
petit mal does not necessarily point to a subcortical 
origin for the generalized discharges, and occasion-
ally, a limbic system focus may mimic the petit mal 
attacks (Fig. 4). The limbic system has been 
demonstrated to extend to subcortical structures as 
well (30). Even in the cases of "typical petit ma!," the 
generalized S & W on EEG may be accompanied by 
complex behavior and automatism which may be en-
vironmentally influenced (31, 32). They may be ac-
companied by increased or decreased postural tone of 
the body (31, 32). The above may explain the com-
plexity of the subject partial seizures and the problem 
of misdiagnosis or incorrect treatment. 
A large number of patients in this study (Tables 
6, 7) suffered from akinetic seizures. This form of 
seizure (33-35) may be accompanied by slow S & W 
discharges on EEG-the "petit ma! variant" (36, 37). 
The akinetic and atonic seizures seem to form a syn-
drome variable in etiologies as well as in EEG find-
ings. The "Lennox syndrome" (37), a name which 
has been used synonymously for these seizures, is 
characterized by 1) age of onset, usually below six 
years of age; 2) complex seizure manifestations, such 
as akinetic and myoclonic seizures; 3) retardation; 4) 
resistance to treatment; and 5) generalized slow S & W 
discharges plus other abnormalities in three-fourths of 
cases (38, 39). Whereas this syndrome comprises the 
majority of akinetic seizures in young children who 
are also retarded, it does not encompass the entire 
spectrum of akinetic seizures. 
When the akinetic seizures occur in the older age 
patients, or in patients who do not have other aspects 
of Lennox syndrome (such as retardation), the 
prognosis seems to be more favorable. This is 
reflected clearly in our study of 32 akinetic seizure 
patients (Table 9). The EEG findings, usually that of 
slow S & W discharges in Lennox syndrome, may 
demonstrate focal discharges in older age patients 
(40-44). Our depth electrode studies confirm cortical 
origin of the epileptogenic focus in some of these 
patients (Figs. 5, 6; Table 7). 
Depth electrode studies may be very helpful in 
care of seizure patients if the following minimal 
criteria are met: 1) the use of the thinnest possible 
depth electrodes; 2) a suggestion of focal discharges on 
surface recording; 3) the confirmation of cerebral 
dominance by intra-arterial amobarbital test before 
any surgical procedure; and 4) the recording of the ic-
tal event from the surgically resectable epileptogenic 
focus. 
In our experience (Table 7), repeated negative 
contrast studies over the years do not rule out the 
possibility of brain tutnor or AV malformation as the 
cause of seizure disorder (Fig. 5). Crandall (45), in his 
experience with depth electrode studies in seven in-
tractable partial seizures, noted one patient suff~ring 
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Fig. 6A-Eleven-year-old girl with intractable seizures and left-
sided hemiplegia since birth. Surface EEG recording shows 
bilateral multispikes. 
from corpus callosum astrocytoma who suffered 
from attacks of becoming rigid and falling backward 
as well as psychomotor seizures. This patient, along 
with another patient who had a small meningeal 
angioma, had negative contrast studies. Page et al. 
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Fig. 6B-Electrocortiography (ECoG) before and after 
hemispherectomy. Right-postoperative surface EEG shows no 
more spikes. Patient is seizure free. No more need for anticonvul-
sant therapy. 
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Fig. ?-Comparison of the results of therapy among seizure 
patients referred to the seizure control clinic. As noted, un-
dermedication and overmedication comprise the majority of 
failure cases. 
( 46), while underlining the importance of brain tumor 
as the causative factor in rare cases of childhood 
seizure disorders, emphasized the fact that a change 
of seizure pattern in EEG or in behavioral school per-
formance should make one suspicious of the 
possibility of brain tumor as the causative factor. 
It is concluded that with adjustment of treat-
ment, accurate diagnostic work-up, trial of new an-
ticonvulsants, and surgical therapy for partial 
seizures, the failure rate may drop from 100% to 20% 
(Table 8, Fig. 7). 
Prevention of Seizure Disorders. The knowledge 
about seizure disorders has advanced to the point of 
considering prevention. 
Prenatal Prevention. Maternal toxoplasmosis, 
syphilis, and cytomegalovirus infections should be 
diagnosed and aggressively treated. Maternal hygiene 
and nutrition play a role in the size of the child. The 
low birth-weight children are at risk for neonatal 
seizure disorders. 
Neonatal and Infantile Prevention. Early 
diagnosis and effective treatment of neon atal 
meningitis can prevent the late complications of in-
tractable seizures. Immunization, especially for 
measles and mumps, should be strongly encouraged. 
Febrile seizures should be aggressively treated and 
prevented by antipyretic and anticonvulsant 
(phenobarbital) therapy to prevent mesial and tem-
poral anoxic damage and subsequent late-onset tem-
poral lobe seizures. 
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Prevention of Head Injury. Prevention of head 
injury by the use of seat-belts in the car, and by en-
couraging the schools to avoid building cement floors 
under swings in the playground can be helpful. 
The Role of Eugenics. The role of eugenics is 
limited to such diseases as Huntington's chorea, 
phenylketonuria, and mucopolysaccharidosis; how-
ever, intermarriage among families with high risk 
seizure disorders may be discouraged. 
Psychosocial Aspects. This is one area where un-
fortunately no recent progress has been made. The 
general public still has a medieval attitude toward 
epileptics. More education for the public as well as 
for health officials is needed. 
Acknowledgment: I would like to thank Dr. 
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Radical Reconstruction of Complex 
Cranio-Orbito-Facial Abnormalities* 
JOHN A. JANE, M.D., Ph.D. and MILTON T. EDGERTON, M.D. 
Departments of Neurosurgery and Plastic Surgery, 
University of Virginia, School of Medicine, Charlottesville 
Introduction. The two possible justifications for 
surgery in craniosynostosis are first, to allow room 
for the growing brain, thus preventing damage to 
developing neural structures and second, to prevent 
or correct deformity. There is considerable doubt 
about the extent to which the first consideration is 
valid. Objective signs of increased intracranial 
pressure are rarely seen with a single closed suture. 
This fact, along with the difficulty in demonstrating 
either impairment or improvement in psychological 
functioning following single suture removal, has led 
to a generally negative view toward synostectomy 
with a closed single suture. On the other hand, there 
is very little question that multiple suture closure can 
lead to increased intracranial pressure, and here, early 
surgery is certainly justified. This ongoing argument 
about the benefits that might accrue with release of 
the fused sutures seems to have prevented growth of 
interest in the purely cosmetic aspects of the 
procedure. Although there is general agreement that 
early release gives better long-term results, there has 
been very little interest in the late effects of syn-
ostosis, such as marked frontal bossing or the as-
sociated facial deformities like those seen in Figure I. 
We have recently been attempting to reconstruct 
complex abnormalities involving the skull, orbit, and 
face at a progressively earlier age. Our cases include 
such conditions as Apert's and Crouzon's syndromes 
and single and multiple premature suture closure. We 
wish to present two illustrative cases, one of a com-
* Presented by Dr. Jane at the 27th Annual Stoneburner Lec-
ture Series, February 7, 1974, at the Medical College of Virginia, 
Richmond. 
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bined unilateral coronal and sagittal synostosis and 
the other, a Crouzon's syndrome. 
Case 1. T. D. was seen at the age of two weeks. 
He showed (Figs. I, 2) the typical appearance of a 
right unilateral coronal combined with a sagittal syn-
ostosis. There was considerable frontal bossing on 
the left side opposite the coronal synostosis, which 
had resulted in depression of his left orbit. He was 
Fig. I-Case I showing flattening of the right brow and depression 
of the left orbit in the instance of combined right coronal and sagit-
tal synostosis. 
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Fig. 2-View from above showing the extent of the left frontal 
bossing resulting in depression of tlie orbit. 
taken to the operating room where the fused sagittal 
suture was removed and used to reconstruct the 
deficient orbital rim on the side of the coronal syn-
ostosis. A dural graft also was placed on this side, 
and the dura was plicated over the side of the frontal 
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Fig. 3-A postoperative view showing improvement in the skull 
shape with some residual depression of the orbit. 
bossing. This resulted in shifting the intracranial con-
tents to the right side with a more normal appearance 
of the skull. We consider this maneuver of 
remoulding the dura to be an important step in the 
long-term results. Figure 3 is a postoperative 
Fig. 4A , B-The typical appearance ofCrouzon's deformity with proptosis, underdevelopment of the maxilla, and relative overdevelop-
ment of the mandible. 
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Fig. 5-Cadaver skull showing the point at which the osteotomy is 
carried out. 
photograph showing excellent skull shape, although 
the orbit is still slightly depressed. facial appearance 
has continued to improve. 
Case 2. Figure 4A, B shows a 13-year-old girl 
with the typical appearance of ~rouzon's disease. 
There is relative µnderdevelopment of the maxilla 
Fig. 7A , B-Postoperative photographs. 
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Fig. 6-0perative photograph showing the frontal bone being 
pulled forward over the orbit. 
and overdevelopment of the mandible with proptosis. 
Our surgical procedure involved a combined in-
tracranial and extracranial approach; one of the 
procedures used is illustrated in Figure 5. The line 
across the frontal fossa indicates the cut that is made 
in the bone. Figure 6 shows the actual operative 
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procedure, the frontal bone being moved forward 
over the orbits to relieve the proptosis. Figure 
7 A, B shows the postoperative results. 
Discussion. These procedures are generally long 
and, particularly when performed on young chil-
dren, considerable care must be taken in the 
mairitenance of blood volume and humidification of 
the respiratory system. In the postoperative period, 
chronic measurement of intracranial pressure has 
also proven to be most helpful. 
The first case illustrates what we think may be an 
important aspect of the early repair of craniofacial 
malformation, that is, the question as to whether 
remodeling of the cranial vault alone, without con-
comitant remodeling of at least the dura, is sufficient 
to obtain good late results. It may well be that the un-
derlying brain and dura are the prime factors respon-
sible for the ultimate shape of the cranial vault as has 
been suggested {I). Experiments in our own 
laboratory also suggest that this is the case. We have 
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performed a series of experiments on neonatal hood-
ed rats, in which we have systematically altered the 
brain or the dura alone or we have altered both 
together. The findings suggest the importance of the 
dura and brain in determining skull shape (2). 
Summary. Excellent cosmetic results can be ob-
tained by early intervention in severe cranial-orbital-
facial deformity. This intervention should take the 
form of a combined intracranial and extracranial ap-
proach. While the procedure is of great magnitude, 
the benefits to the patient and to the family seem 
worth the risk. 
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Progress and Problems 1n the 
Rehabilitation of Patients with 
Central Nervous System Injuries* 
L. D. AMICK, M.D. 
Professor and Chairman, Department of Physical Medicine and Rehabilitation; 
Professor of Neurology, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond 
The Stoneburner lecturer and other colleagues 
have discussed diverse pathologies which may create 
a wide spectrum of lesions and dysfunctions of the 
central nervous system. Rehabilitation medicine is 
primarily involved in the care of patients with 
disabilities of skilled motor performance, which 
commonly result from neurologic impairment. Ad-
ditional alterations in performance may be con-
tributed by personality, as well as societal and 
cultural backgrounds. Rehabilitation is particularly 
opportune when the diseases causing disability are 
static, are in prolonged remission, or are only slowly 
progressing. Central nervous system dysfunction may 
involve sensory, motor, and cognitive performance as 
well as psychologic issues. Rehabilitation considered 
here is the prevention, minimization, and functional 
compensation for neurologic disability. Reha-
bilitative principals and methods, such as position-
ing, padding, and range of motjon to avoid decubiti 
and contractures, with strengthening exercises, 
and with orthotic and prosthetic devices, usually 
apply regardless of etiology of the lesions but do 
not obviate the need for enlightened individuation of 
therapy and the provision of continuing medical 
management. 
Let us briefly consider the general nature of con-
temporary rehabilitation with highlights of its 
* Presented by Dr. Amick at the 27th Annual Stoneburner 
Lecture Series, February 8. 1974, at the Medical College of 
Virginia, Richmond. 
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progress and problems. Paraplegia and hemiparesis 
may be thought of as the models of neurologic 
impairment. 
Psychologists such as Fink, Maslow, and Benton 
have made brilliant contributions to modern 
rehabilitation. Their theoretical models of the 
processes of human adaptation under stress have 
proved important and useful in dealing with the 
problems of motivation. A stressful event is a crisis 
when the patient's normal coping ability is inade-
quate for the event. A major neurologic catastrophe 
is such a crisis and is a turning point in the life of a 
patient (Table I). After the initial neurologic shock in 
terms of coma or confusion and atony or areflexia, 
the patient's awareness brings initial psychologic 
shock marked by anxiety and/ or bewilderment. The 
initial stages of recovery and improvement of 
neurologic function favor his hope for further gain, 
but any considerable persisting disability is usually 
rejected by the patient as temporary, since he wishes 
and assumes that structure and function will be fully 
returned. During this psychologic phase of defensive 
retreat and relief of anxiety, possibly even to the 
point of euphoria, it not only is not useful for us to 
confront the patient with dire facts and probabilities 
but is even likely to prove deleterious, this is because 
once we, as therapeutic agents, are associated with 
anxiety reinforcement, we are less likely to be 
accepted later as a constructive guiding force . The 
next psychologic phase of admission or acknowledge-
ment of di&ability accompanies the completion of any 
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TABLE I 
Crisis and Motivation 
Time Precipitant Psychologic Phase 
Acute somatic Shock 
damage 
Physical recovery Retreat 
Early plateau Admission 
Final plateau Adaptation 
w 
early improvement and the establishment of an early 
plateau of disability. The patient now faces reality 
with reactive depression and possibly self-
depreciation or bitterness. During this renewal of 
stress, therapeutic support may be critical, and it is 
fitting and useful to emphasize the support and 
acceptance that the institution and therapists are con-
tinuing to provide for the patient. This is based upon 
the simple dichotomy of Maslow that people have 
basic safety needs pertaining to food, health, security, 
and predictable environment, and that these safety 
needs are a chassis on which are erected the growth 
needs of greater independence, personal achievement, 
and creativity. A positive therapeutic environment 
takes advantage of the final phase of adaptation, oc-
curring when the patient faces the structure of dis-
ability combined with residual capability and 
progresses to the struggle for renewed independence, 
which will require a different utilization of resources 
in his life and reorganization for the future. I should 
like to quote a paraplegic physician and 
physiatrist, who says, "Management of spinal cord 
injury is, today, seriously handicapped by almost ex-
clusive emphasis upon physiologic and pathologic 
processes. I believe that greater progress in com-
prehensive care will be achieved when a true integra-
tion is reached in physical and psychosocial therapy." 
Another major concept that has emerged as an 
integral part of modern rehabilitation is that of the 
comprehensive regional rehabilitation center. Stan-
dard-bearers exemplifying this approach are Stoke-
Mandeville (England) National Paraplegic Center, 
Georgia Warm Springs Foundation, NYU-Bellevue 
Institute of Physical Medicine and Rehabilitation, 
and Rancho Los Amigos, California. This concept is 
further being supported and tested by the federal 
government in the recent proliferation of spinal cord 
Self-Image Affect and Cognition 
Structural threat Overwhelming anxiety; 
cannot plan, understand 
"Regain" structure Avoids reality; autistic; resists 
change 
Give up structure; Faces imposing reality; 
self-depreciation depressed ± bitter 
Form new structure; New reality, satisfactions; 
renewed self-worth reorganizes resources, future 
tnJury centers in this country adding to the preexist-
ent ones in a few VA hospitals. Much significant 
research and development have emanated from these 
centers. Virginia is privileged to have three such 
centers, some of whose contributions will be men-
tioned, at the McGuire VA Hospital in Richmond, at 
the Tower Hospital for traumatic paraplegics in 
Charlottesville, and at the the Woodrow Wilson 
Rehabilitation Center in Fishersville. A medical 
school has regional and exemplary functions and 
should itself, through a department of rehabilitation 
medicine or through its affiliates, develop a com-
prehensive rehabilitation center. We have embarked 
on this course at the Medical College of Virginia. 
Another major concept has been evolving at the 
direct therapeutic level-the concept of organ reserve 
applied to the brain, sometimes called cerebral 
plasticity, which contends that surviving cerebral 
parenchyma may be trained to perform the functions 
of destroyed tissue. This phenomenon must be distin-
guished from restored function in temporarily 
malfunctioning but intact tissue. A good example is 
found in disability caused by cortical sensory defects. 
We are familiar with the loss of recognition of objects 
being handled, a loss of stereognosis, due to a parietal 
lobe lesion. Ruch and Fulton earlier demonstrated in 
primates that when one of three principal regions of 
sensory cortex is ablated there is a marked decrease in 
stereognosis but, with further training, this function 
will return . Forster and Shields pointed out the 
implication that we may retrain patients to recover 
stereognostic function . Instances of improvement 
following such retraining in occupational therapy oc-
cur, although there are obvious limits to this process. 
Closely related to this concept are the various 
methodic approaches to the physical therapy of 
voluntary motor dysfunction based upon propriocep-
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tive or reflex facilitation. Cohen's experimental 
results showed that while the effect of such facilita-
tion of the limbs upon cortically induced muscle con-
tractions could be generalized for the whole popula-
tion, the influence, whether facilitatory or inhibitory, 
of a given sensory stimulus in a single individual 
remained consistent under repetitive testing. We are 
appropriately skeptical of specific "method schools" 
of therapy, but we welcome the safe, empirical trial of 
various techniques in some individual patients. 
The concept of operant conditioning explored by 
Skinner and Bachrach is currently in vogue and is 
being vigorously tested in a number of rehabilitation 
centers; it essentially supports a learning theory that a 
voluntary choice or act on the part of patient may be 
rewarded so that he will choose to repeat the act and 
thus may eventually perfect it-positive reinforce-
ment of behavior and means of motivation. Benton, 
Blackburn, and Shankweiler specifically studied 
motivational influences on performance in brain-
damaged patients and controls. Standard retest in-
structions brought little change but both "urging" in-
structions and "failure" instructions that told the 
patient he was not doing well resulted in significant 
improvements in performance in both groups. There 
was no breakdown in performance in the face of this 
degree of stress. By contrast, both instructions to 
"relax" and "success" instructions telling the patient 
he was doing very well brought only small or no im-
provement in performance. They conclude that a 
complete concept of motivation includes readiness to 
engage in specific modes of behavior as well as a drive 
level of sufficient strength to energize that behavior. 
This internal state of the organism consisting of drive 
level and behavior-readiness is decisive in deter-
mining the possibility and rate of modification of 
behavior in learning situations. 
Let us descend for a moment from the brain to 
the bladder. Spinal cord injury often disturbs bladder 
function, and ever after we must also continue to 
share with the patient a concern for preservation of 
the upper urinary tract. Urostasis and insertion of 
catheters lead to urinary infection which readily 
ascends. Another renal threat is back pressure from 
obstruction or vesicoureteral reflux. Cord injury 
above the conus gives a spastic bladder, called 
automatic or reflex, that may empty in a sporadic, 
unpredictable manner either without a catheter or 
around a catheter. If residual urine is modest, this 
reflex bladder is satisfactory, particularly in men who 
learn to use an external collecting appliance. Diffi-
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culty arises when spasticity spreads to the external 
urethral sphincter and blocks urinary outflow. When 
detrusor pressure dominates over the sphincter, we 
have a so-called "balanced bladder," whereby we 
may say that the spasticity which creates a reflex 
bladder is good. But spasticity which is severe or ex-
cessive is apt to involve the sphincter and be un-
favorable. In fact, we have learned that decubitus, 
calculus, infection, and indwelling catheters are po-
tent stimuli to cord facilitation which can lead to ex-
cess spasticity and obstruction to urinary outflow. 
Abramson even contends that the nature of the 
spasticity after cord injury "seems to be permanently 
influenced by the consistency with which noxious 
stimuli arrive at the cord during its (posttraumatic) 
functional reorganization." The special importance 
of preventing these early complications becomes ob-
vious. Guttmann at Stoke-Mandeville proved that in-
termittent catheterization from the beginning, never 
resorting to the indwelling catheter, will keep the 
urine sterile and so allow greater residual toleration 
without risk of ascending infection. This has been 
verified in this country in hospitals where the re-
quired but expensive personnel utilization has been 
funded. Nevertheless, imbalance between detrusor 
and sphincter tone may occur. Bunts and Hackler 
at McGuire VA Hospital followed Gibbons' lead to 
develop the external sphincterotomy to decrease 
urethral resistance and thus to restore balance. This 
succeeded in restoring a negligible postvoiding 
residual urine in 74% of 150 patients, the majority of 
whom have maintained this good result beyond five 
years. Given a permanent neurologic defect, the wish 
to eliminate use of the indwelling catheter, residual 
urine more than 30 percent of bladder capacity, 
and a pos1t1ve sphincterometrogram, Bunts 
and Hackler favor such surgery without further 
delay. They have found pudenda) neurectomy to be 
less effective. Regular six-month reevaluations, in-
cluding cystourethrogram, appear advisable for all 
paraplegic bladders. If reflux or a small spastic 
bladder develops, Bunts and Hackler then advise a 
selective rhizotomy to convert the spastic reflex 
bladder to a lower motor neuron or flaccid bladder. 
The latter may be emptied by abdominal contraction 
or Crede maneuver. They consider surgeries at the 
ureteral level such as ileal conduit only as a later 
resort. 
Several other research developments are also 
worth mentioning. Kantowitz implanted a radio-
linked bladder stimulator in three male paraplegic 
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patients with variable results-the electrodes might 
corrode and might lose their position in the bladder 
wall, and an effective voltage might close the external 
sphincter. Grimes (Fig. 1). Nashold, and Currie at 
Duke University reported last year that they have 
implanted electronic stimulators (neuroprostheses) 
directly into the sacral spinal cord itself in five 
paraplegic patients. One patient had a temporary 
tendency to autonomic hyperreflexia and male 
patients obtained penile erection from such stimula-
tion and three patients have maintained good 
bladders by this means for more than a year. Others 
have even proposed to restore a functional gait in 
paraplegic man by programming the electronic 
stimulation of peripheral nerves in series, intending 
to produce muscle contractions in a pattern of am-
bulation. Nooney at MCV has developed a tiny mir-
ror attachment for spectacles to permit awareness 
of the blind side in homonymous hemianopia. Rob-
inson and Warner at the Yerkes Regional Primate 
Research Center have evoked certain behavior pat-
terns in monkeys using remote control telestimu-
lation (Fig. 2). In a more extensive study (of elec-
trically controlled behavior in animals, von Holst and 
von Saint Paul at the Max Plank Institute for the 
Physiology of Behavior in Seewiesen, Germany, were 
able with brain electrodes to make the chicken carry 
out most of the actions of its normal repertory and 
thus clarify the nature of its drives (Fig. 3). In the up-
per and lower photograph at the left, a formerly in-
Fig. I-Implantable stimulator and electrode assembly with por-
table transmitter. 
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Fig. 2-Mounting evoked by telestimulation of the lateral 
hypothalamus. 
different rooster was electrically stimulated to attack 
a small stuffed predator, culminating in attack with 
spurs and triumphant call. At the right, the same 
rooster which had always treated the keeper as a 
friend is shown attacking the keeper's face which 
appears to be a better substitute for an enemy than 
her hand. If all substitutes for an enemy are lacking, 
the rooster exhibits only motor restlessness. They 
concluded from duplicating various natural drives 
that stimulation of the brain stem set off essentially 
complete and normal processes and that effects of 
stimulation are therefore not imitations or "pseudo-
affective" states but genuine drives. " The organ-
ism comprises a bundle of drives which support 
one another or oppose one another to greater or 
lesser extent. Spontaneous activity is the result of a 
continual and shifting interplay in forces of the cen-
tral nervous system." Freedman et al report that elec-
trical stimulation of the septal brain area in humans 
has halted epileptic seizures, dulled the pain of 
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Fig. 3. 
I 
\ I 
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cancer, produced sexual pleasure, and brought relief 
from anger and frustration. 
It is difficult to predict what ethical dilemmas 
future technological developments may bring, but in 
the sweep of progress, we expect that CNS function 
will be spared and restored as a result of further 
breakthroughs in biologic and behavioral research. 
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how big a dose will now 
bring relief ii it is a narcotic? 
"Tolerance is an ever-present hazard to continued use 
of narcotics .... The very first dose diminishes the 
effects of subsequent doses."! And, as increasing 
amounts of narcotics are required to control pain, dis-
tressing adverse effects-lethargy, hypotension, con-
stipation, etc.-can needlessly debilitate the patient. 
1. Sadove, M. S.: A look at narcotic and non-narcotic analgesics, 
Postgrad. Med. 49:102, June 1971. 
how big a dose will now 
bring relief ii it is Talwin®? 
Chances are, the same 50 mg. Talwin Tablet you pre-
scribe originally will continue to provide good pain 
relief. Talwin can be compared to codeine in analgesic 
efficacy: one 50 mg. tablet appears equivalent in anal-
gesic effect to 60 mg. (1 gr.) of codeine. However, 
patients receiving Talwin Tablets for prolonged periods 
face fewer of the consequences you've come to expect 
with narcotics. There should be fewer "adverse effects" 
on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of Talwin 
Tablets is rare. 
Dependence rare: During three years of wide clinical use, 
there have been a few reports of dependence and of with-
drawal symptoms with orally administered Ta/win. Patients 
with a history of drug dependence should be under close 
supervision while receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient 
and to prevent the use of the drug in anticipation of pain 
rather than for the relief of pain.* 
Generally well tolerated by most patients*: Infrequently 
causes decrease in blood pressure or tachycardia; rarely 
causes respiratory depression or urinary retention; seldom 
causes diarrhea or constipation. Acute, transient CNS effects, 
described in product information, have occurred in rare 
instances following the use of Talwin Tablets. If dizziness, 
lightheadedness, nausea, or vomiting is encountered, these 
effects may decrease or disappear after the first few doses. 
*See important product information for adverse reactions, patient 
selection, prescribing and precautionary recommendations. 
in chronic pain 
of moderate to severe intensity 
Talw'in®::i. 
Talwin® Tablets brand of pentazocine (as hydrochloride) 
Analgesic for Oral Use -
Indication: For the relief of moderate to severe pain. 
Contraindication: Talwin should not be administered to patients who are 
hypersensitive to it. 
Warnings: Drug Dependence. There have been instances of psychological 
and physical dependence on parenteral Ta/win in patients with a history of 
drug abuse and, rarefy, in patients without such a history. Abrupt discon· 
tinuance to/lowing the extended use of parenteral Ta/win has resulted in 
withdrawal symptoms. There have been a few reports of dependence and of 
withdrawal symptoms with orally administered Ta/win. Patients with a his-
tory of drug dependence should be under close supervision while receiving 
Ta/win orally. 
In prescribing Ta/win tor chronic use, the physician should take precautions 
to avoid ingeases in dose by the patient and to prevent the use of the drug 
in anticipation of pain rather than for the relief of pain. 
Head tn1ury and Increased /ntracraniat Pressure. The respiratory depressant 
effects of Talwin and its potential for elevating cerebrospinal fluid pressure 
may be markedly exaggerated in the presence of head injury, other intra-
cranial lesions, or a preexisting increase in intracranial pressure. Further-
more, Talwin can produce effects which may obscure the clinical course of 
patients with head injuries. In such patients, Talwin must be used with ex-
treme caution and only if its use is deemed essential. 
Usage in Pregnancy. Safe use of Talwin durini: pregnancy (other than labor) 
has not been established. Animal reproduction studies have not demon-
strated teratogenic or embryotoxic effects. However, Talwin should be 
administered to pregnant patients (other than labor) only when, in the judg-
ment of the physician, the potential benefits outweigh the possible hazards. 
Patients receiving Talwin during labor have experienced no adverse effects 
other than those that occur with commonly used analgesics. Talwin should 
be used with caution in women delivering premature infants. 
Acute CNS Manifestations. Patients receiving therapeutic doses of Talwin 
have experienced, in rare instances, hallucinations (usually visual), dis-
orientation, and confusion which have cleared spontaneously within a 
period of hours. The mechanism of this reaction is not known. Such patients 
should be very closely observed and vital signs checked. If the drug is re-
instituted it should be done with caution since the acute CNS manifesta-
tions may recur. 
Usage in Children. Because clinical experience in chi ldren under 12 years of 
age 1s limited, administration of Talwin in this age group is not recommended . 
Ambulatory Patients. Since sedation, dizziness, and occasional euphoria 
have been noted, ambulatory patients should be warned not to operate 
machinery, drive cars, or unnecessarily expose themselves to hazards. 
Precautions: Certain Respiratory Conditions. Although respiratory depres-
sion has rarely been reported after oral administration of Talwin, the drug 
should be administered with caution to patients with respiratory depression 
from any cause, severely limited respiratory reserve, severe bronchial 
asthma and other obstructive respiratory conditions, or cyanosis. 
Impaired Renal or Hepatic Function. Decreased metabolism of the drug by 
the liver in extensive liver disease may predispose to accentuation of side 
effects. Although laboratory tests have not indicated that Talwin causes or 
increases renal or hepatic impairment, the drug should be administered 
with caution to patients with such impairment. 
Myocardial Infarction. As with all drugs, Talwin should be used with caution 
in patients with myocardial infarction who have nausea or vomiting. 
Biliary Surgery. Until further experience is gained with the effects of Talwin 
on the sphincter of Oddi, the drug should be used with caution in patients 
about to undergo surgery of the biliary tract. 
Patients Receiving Narcotics. Talwin is a mild narcotic antagonist. Some 
patients previously given narcotics, including methadone for the daily treat-
ment of narcotic dependence, have experienced withdrawal symptoms after 
receiving Talwin. 
CNS Effect. Caution should be used when Talwin is administered to pa-
tients prone to seizures; seizures have occurred in a few such patients in 
association with the use of Talwin although no cause and effect relationship 
has been established. 
Adverse Reactions: Reactions reported after oral administration of Talwin 
include gastrointestinal: nausea, vomiting; infrequently constipation; and 
rarely abdominal distress, anorexia, diarrhea. CNS effects: dizziness, light-
headedness, sedation, euphoria, headache; infrequently weakness, dis-
turbed dreams, insomnia, syncope, visual blurring and focusing difficulty, 
hallucinations (see Acute CNS Manifestations under WARNINGS); and rarely 
tremor, irritability, excitement, tinnitus. Autonomic: sweating; infrequently 
flushing; and rarely chills. Allergic: infrequently rash; and rarely urticaria, 
edema of the face. Cardiovascular: infrequently decrease in blood pressure, 
tachycardia . Hematologic: rarely depression of white blood cells (especially 
granulocytes), usually reversible and usually associated with diseases or 
other drugs which are known to cause such changes, moderate transient 
eosinophiloa. Other: rarely respiratory depression, urinary retention, toxic 
epidermal necrolysis. 
Dosage and Administration: Adults. The usual initial adult dose is 1 tablet (50 mg.) every three or four hours. This may be increased to 2 tablets (100 
mg.) when needed. Total daily dosage should not exceed 600 mg. 
When antiinflammatory or antipyretic effects are desired in addition to 
analgesia, aspirin can be administered concomitantly with Talwin. 
Children Under 12 Years of Age. Since clinical experience in children ynder 
12 years of age is limited, administration of Talwin in this age group 1s not 
oeJr~7)~eg?'j.i·erapy. Patients with chronic pain who have received Talwin 
orally for prolonged periods have not experienced withdrawal symptoms 
even when administration was abruptly discontinued (see WARNINGS). No 
tolerance to the analgesic effect has been observed. Laboratory tests of 
blood and urine and of liver and kidney function have revealed no signifi-
cant abnormalities after prolonged administration of Talwln. 
Overdosage: Manifestations. Clinical experience with Talwin overdosage has 
been insufficient to define the signs of this condition. 
Treatment. Oxygen, intravenous fluids, vasopressors, and other supportive 
measures should be employed as indicated. Assisted or controlled ventila-
tion should also be considered. Although nalorphine and levallorphan are 
not effective antidotes for respiratory depression due to overdosage or un-
usual sensitivity to Talwin, parenteral naloxone (Narcan®, available through 
Endo Laboratories) is a specific and effective antagonist. 
Talwin is not subject to narcotic controls. 
How Supplied: Tablets, peach color, scored. Each tablet contains Talwin (brand of pentazocine) as hydrochloride equivalent to 50 mg. base. Bottles 
of 100. 
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A service to medical education from A. H. Robins: ;.Gl 
~;~he:Gpted fro•mlV.olume 2 The A . H. Robins G I Series consists of six book- ,~;;::::.. 
lets, designed to provide a quick. yet comprehen-
sive review of basic procedures and practices in S G .I. medicine - with particular emphasis on the erles physical examination as performed in lhe office or at bedside If you have teaching respons1bilit1es. ' 
limited quantities are available: Part 1 - /nspec110n. 
Part 2 - Palpation . Part 3 - Percuss;on. Part 4 - Auscullaf/on. Part 5 -
Abdominaf Pain and Part 6 - 0ifferent1af 01agnos1s of Abdominal on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A}; the lower pole of the 
right kidney (B}; the abdominal 
aorta CC}; the descending colon 
and the sigmoid (D}; the ascend-
ing colon (E}; and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease}. 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, pancreas, 
stomach, small intestine, trans-
verse colon and spleen. 
Disorders. Write to: The Medical Department. A H . Robins Company, 
1407 Cummings Drive. Richmond . Virginia 23220 
A service to medical education from A. H. Robins: 
Excerpted from Volume 2 
oflheG.I. 
Sen es 
on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A); the lower pole of the 
right kidney (BJ; the abdominal 
aorta (CJ: the descending colon 
and the sigmoid (DJ; the ascend-
ing colon (El: and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, pancreas. 
stomach, small intestine, trans-
verse colon and spleen. 
The A H Robins G I Series consists of six book-
lets. designed to provide a quick. yet comprehen-
sive review of basic procedures and practices 1n 
G I m edicine-with particular emphasis on the 
physical exam1nat1on as performed in the office or 
at bedside If you have teaching respons1bl11t1es. 
l1m1ted Quant1lles are available: Part 1 lnspeclion. 
Part 2-Palpalion. Part 3 - Percuss,on. Part 4 - Auscultation. Part 5-
Abdominal Pain and Part 6 - 0ifferent1al Diagnosis of Abdominal 
Disorders Write to: The Medical Department. A H Robins Company. 
t407 C ummings Drive. Richmond . Virginia 23220 
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each tablet. 
capsule or 5 cc. 
teaspoonful 
of elixir (23% alcohol) 
hyoscyamine sulfate 0 . 1 037 mg. 
atropine sulfate 0.0194 mg. 
hyoscine hydrobromide 0.0065 mg. 
each 
Don natal 
No. 2 
0.1037mg. 
0.0194 mg. 
00065mg. 
Phenobarbital (JI.I gr.) 16.2 mg 
(warning may be habit forming) 
(1-2 gr.) 32.4 mg. 
each 
Ex ten tab 
0.3111 mg. 
0.0582mg. 
0.0195mg. 
(o/. gr.) 48.6 mg. 
• 
• Brief summary. Adverse Reactions: Blurring of vision, dry mouth, 
difficult urination, and flushing or dryness of the skin may occur 
on higher dosage levels, rarely on usual dosage. Contraindica-
tions: Glaucoma; renal or hepatic disease; obstructive uropathy 
(for example, bladder neck obstruction due to prostatic hyper-
trophy}: or hypersensitivity to any of the ingredients. 
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Before prescribing, please consult 
complete product information, a sum-
mary of which follows: 
Indications: Tension and anxiety 
states, somatic complaints which are 
concomitants of emotional factors; psy-
choneurotic states manifested by tension, 
anxiety, apprehension, fatigue, depres-
sive symptoms or agitation; symptomatic 
relief of acute agitation. tremor. delirium If therie·s tremens and hallucinosis due to acute A 
alcohol withdrawal; adjunctively in skele-
tal muscle spasm due to reflex spasm to 
local pathology, spasticity caused by d 
upper motor neuron disorders, athetosis, goo rieason to 
stiff-man syndrome, convulsive disorders 
(not for sole therapy). 
contraindicated: Known hypersensi- pfle.SCfI.be fiOf tivity to the drug. Children under 6 
months of age. Acute narrow angle glau-
coma; may be used in patients with open ~~i~lt~ ~~eur~~~-a who are receiving appro- PS¥Ch1·c tens1jon ... 
Warnings: Not of value in psychotic ~ 
patients. Caution against hazardous 
occupations requiring complete mental 
alertness. When used adjunctively in con- ~ 
seizures may require increased dosage of \_ ,. _ I in frequency and/ or severity of grand mal l ... - !, . _ \"~ . _---: - -~ 
vulsive disorders, possibility of increase M-
standard anticonvulsant medication; ~~~~~ ~-- ~ · , -
abrupt withdrawal may be associated ~  - 7 ~ = 
with temporary increase in frequency ~ • ~~. . ~1\~~ ~ \ ' and/ or severity of seizures. Advise _ 
against simultaneous ingestion of alcohol 
and other CNS depressants. Withdrawal 
symptoms (similar to those with barbitu- \ 
rates and alcohol) have occurred follow-
ing abrupt discontinuance (convulsions, 
tremor, abdominal and muscle cramps, 
vomiting and sweating). Keep addiction-
prone individuals under careful surveil- - . 
lance because of their predisposition to 
habituation and dependence. In preg-
nancy, lactation or women of childbearing 
age, weigh potential benefit against 
possible hazard. 
Precautions: If combined with other 
psychotropics or anticonvulsants, con-
sider carefully pharmacology of agents 
employed; drugs such as phenothiazines, 
narcotics, barbiturates, MAO inhibitors 
and other antidepressants may potentiate 
its action. Usual precautions indicated in 
patients severely depressed, or with latent 
depression, or with suicidal tendencies. 
Observe usual precautions in impaired 
renal or hepatic function. Limit dosage to 
smallest effective amount in elderly and 
debilitated to preclude ataxia or over-
sedation. 
Side Effects: Drowsiness, confusion, 
diplopia, hypotension, changes in libido, 
nausea, fatigue, depression, dysarthria, 
jaundice, skin rash, ataxia, constipation, 
headache, incontinence, changes in sali-
vation, slurred speech, tremor, vertigo; 
urinary retention, blurred vision . Para-
doxical reactions such as acute hyper-
excited states, anxiety, hallucinations, 
increased muscle spasticity, insomnia, 
rage, sleep disturbances, stimulation 
have been reported; should these occur, 
discontinue drug. Isolated reports of neu-
tropenia, jaundice; periodic blood counts 
and liver function tests advisable during 
long-term therapy. ® Roche Laboratories Division of Hoffmann-La Roche Inc. 
Nutley, N.J. 07110 
When, for example, despite counseling, 
tension and anxiety continue to produce 
distressing somatic symptoms 
. Promnt action is a gooCI reason to 
consider Valium (diazepam) 
2-mg, 5-mg, 10-mg tablets 
